curriculum vitae - University of South Florida

CURRICULUM VITAERobert A. Hauser, M.D., M.B.A.BUSINESS ADDRESS:HOME ADDRESS:University of South Florida2575 Regal River RoadParkinson’s Disease and Movement Disorders Center Valrico, Florida 335494 Columbia Drive, Suite 410Tampa, Florida 33606Phone: (813) 844-4077Fax: (813) 844-4456_____________________________Robert A. Hauser, M.D., M.B.A.EDUCATIONB.A. Brandeis University 1978Waltham, Massachusetts(Magna cum laude)M.D. Temple University School of Medicine 1982Philadelphia, PennsylvaniaM.B.A. University of South Florida 2000Tampa, FloridaCERTIFICATIONSBoard Certified in NeurologyBy the American Board of Psychiatry and NeurologyNovember, 1989Certified in MRIBy the American Society of NeuroimagingMarch, 1990

2INTERNSHIPPGY-I Albert Einstein Medical Center 7/82-6/83Philadelphia, PennsylvaniaSurgery IRESIDENCYPGY-II, III Eastern Virginia Graduate School 7/83-6/85of MedicineNorfolk General HospitalNorfolk, VirginiaNeurosurgery I, IIPGY-IV, V Eastern Virginia Graduate School 7/85-6/87of MedicineNorfolk General HospitalNorfolk, VirginiaNeurology I, IIPGY-VI Eastern Virginia Graduate School 7/87-6/88of MedicineNorfolk General HospitalNorfolk, VirginiaNeurology III - Chief Resident in NeurologyMaster of Business Administration (M.B.A)University of South Florida 4/2000

3POSITIONS HELDNeurologist 7/88-12/88Neurology SpecialistsNorfolk, VirginiaMovement Disorders Fellow 1/89-6/90With C.W. Olanow, M.D.University of South FloridaTampa, FloridaInstructor 1/90-6/90University of South FloridaTampa, FloridaAssistant Professor of Neurology 7/90-6/96University of South FloridaTampa, FloridaAssistant Director 7/90-7/94Movement Disorders CenterUniversity of South FloridaTampa, FloridaDirectorParkinson’s Disease and Movement Disorders CenterUniversity of South FloridaTampa, Florida7/94-PresentChief 9/94-1/05Section of NeurologyTampa General HospitalTampa, FloridaCo-Director 4/96-6/98Neuro ICUTampa General HealthcareTampa, FloridaAssociate Professor of Neurology, 7/96- 7/01Pharmacology and Experimental TherapeuticsUniversity of South FloridaTampa, FloridaRotating Vice ChairmanDepartment of NeurologyUniversity of South FloridaTampa, Florida 10/03-10/04

4Professor of Neurology,Pharmacology and Experimental TherapeuticsUniversity of South FloridaTampa, FloridaMedical DirectorFlorida Coalition to Cure PD7/01 - Present1/01 – Present

5MEMBERSHIPSAmerican Medical AssociationAmerican Academy of NeurologyAmerican Society of NeuroimagingMovement Disorders SocietyParkinson Study GroupAmerican Society of Neural TransplantationHuntington Study GroupFellow Member, American Academy of Neurology, 2004 – presentNATIONAL COMMITTEE MEMBERSHIPS AND SERVICEMember, Executive Committee, American Academy of Neurology, Section on InterventionalNeurology 1995-1999Surgical Approaches Working Group, Huntington’s Study Group 1995-2004Nominating Committee, Parkinson Study Group 1997Nominating Committee, American Society of Neural Transplantation 1996-1997Nominating Committee, American Academy of Neurology, Movement Disorders Section 1998-2000Scientific Advisory Council, Huntington’s Disease Society of America 1998-2000Nominating Committee, Parkinson Study Group 1999Secretary, Executive Committee, American Academy of Neurology, Section onInterventional Neurology, 1999-2000Nominating Committee, Huntington Study Group, 2000Member, Executive Committee, American Academy of Neurology, Section on Movement Disorders2001-presentVice Chairman, American Academy of Neurology, Section on Interventional Neurology, 2001-2003Member, Center Program and Education Advisory Committee, Huntington’s Disease Society ofAmerica, 2001-2003Chairman, American Academy of Neurology, Section on Interventional Neurology, 2003-presentExecutive Committee, Parkinson Study Group. 2004-present

6LICENSESFlorida 54906

7MANUSCRIPTS1. Hauser RA, Lacey DM, Knight MR. Hypertensive encephalopathy: magnetic resonance imagingdemonstration of reversible cortical and white matter lesions. Arch Neurol 1988;45:1078-1083.2. Rish BL, Hauser RA. Osteopetrosis: A review of a bone disease with neurological sequelae requiringsurgical management. Neuro-Orthopedics 1988;5:112-118.3. Hauser RA. Cerebral Hypoxia. Etiology, sequelae, and intervention. Resident and Staff Physician1988;34(11):43-50.4. Hauser RA, Olanow CW. Effective Parkinson’s treatment. An update on strategy. Senior patient.1990;2:26-31.5. Hauser RA, Olanow CW. Critical drug appraisal. Pergolide. Drug Therapy 1990;20;62-71.6. Hauser RA, Alden SL, Coar DN, Cundiff MR, Bundshuh CC. Intramedullary spinal cord sarcoidosismimicking glioma by magnetic resonance imaging. Paraplegia 1991;29:203-206.7. Hauser RA, Olanow CW. Critical drug appraisal. Pergolide. P&T 1991;16(7):643-654.8. Woodward WR, Olanow CW, Beckner RM, Hauser RA, Gauger LL, Cedarbaum JM, Nutt J. Theeffect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasmaand ventricular CSF L-dopa levels and clinical responses. Neurology 1993;43:1704-1708.9. Hauser RA, Olanow CW. Oro-buccal dyskinesia associated with trihexyphenidyl therapy in a patientwith Parkinson’s disease. Movement Disorders 1993;8:512-514.10. Griffin DK, Shriver ME, Hauser RA. Parinaud’s syndrome as the initial manifestation of acquiredimmunodeficiency syndrome. J Neuroimaging 1994;4:113-114.11. Hauser RA, Olanow CW. Magnetic resonance imaging of neurodegenerative disorders. JNeuroimaging 1994;4:146-158.12. Hauser RA, Trehan R. Initial experience with electroconvulsive therapy for progressive supranuclearpalsy. Movement Disorders 1994;9:467-469.13. Koller WC, Busenbark K, Miner K, and the Essential Tremor Study Group (including Hauser RA).The relationship of essential tremor to other movement disorders: Report on 678 patients. Ann Neurol1994;35:717-723.14. Hauser RA, Zesiewicz TA, Rosemurgy AS, Martinez C, Olanow CW. Manganese intoxication andchronic liver failure. Ann Neurol 1994;36:871-875.15. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJG, Mufson EJ, Sanberg PR, Hauser RA, SmithDA, Nauert GM, Perl DP, Olanow CW. Neuropathological evidence of graft survival and striatal

8reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease.NEJM 1995;332:1118-24.16. Hauser RA, Zesiewicz TA. Sertraline-induced exacerbation of tics in Tourette’s syndrome.Movement Disorders 1995;10:682-684.17. Olanow CW, Hauser RA, Gauger LL, Malapira T, Koller W, Hubble J, Busenbark K, Lillienfeld D,Esterlitz J. The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol1995;38:771-777.18. Freeman TB, Olanow CW, Hauser RA, Nauert GM, Smith DA, Borlongan CV, Sanberg PR, HoltDA, Kordower JH, Vingerhoets FJG, Snow BJ, Snow BA, Calne D, Gauger LL. Bilateral fetal nigraltransplantation into the post commissural putamen in Parkinson’s disease. Annals of Neurology1995;38:379-388.19. Hauser RA, Zesiewicz TA, Martinez C, Rosemurgy AS, Olanow CW. Blood manganese correlateswith brain magnetic resonance imaging changes in patients with liver disease. Canadian Journal ofNeurological Sciences 1996;23:95-98.20. Hauser RA, Murtagh FR, Akhter K, Gold M, Olanow CW. Magnetic resonance imaging ofcorticobasal degeneration. Journal of Neuroimaging 1996;6:222-226.21. Borlongan CV, Freeman TB, Hauser RA, Cahill DW, Sanberg PR. Cyclosporine-A increaseslocomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism: relevance to neuraltransplantation. Surgical Neurology 1996;46:384-388.22. Parkinson Study Group, Kieburtz K, primary author (including Hauser RA). Effect of lazabamide onthe progression of disability in early Parkinson’s disease. Ann Neurol 1996;40:99-107.23. Hauser RA, Zesiewicz TA. Manganese and liver disease. Movement Disorders 1996;11:589.24. Block G, Liss C, Reines S, Irr J, Nibbelink D, and the CR First Study Group (including Hauser RA).Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease: Amulticenter 5-year study. Eur Neurol 1997;37:23-27.25. Hauser RA, Zesiewicz TA, Factor SA, Guttman M, Weiner WJ. Clinical trials of add-on medicationsin Parkinson’s disease: efficacy versus usefulness. Parkinsonism & Related Disorders 1997;3:1-6.26. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease.Movement Disorders 1997;12:756-759.27. Parkinson Study Group (including Hauser RA). Safety and efficacy of pramipexole in earlyParkinson’s disease. A randomized dose-ranging study. JAMA 1997; 278:125-130.28. Borlongan CV, Koutzouzis TK, Freeman TB, Hauser RA, Cahill DW, Sanberg PR. Hyperactivityand hypoactivity in a rat model of Huntington’s disease: the systemic 3-nitropropionic acid model. BrainResearch Protocols 1997;1:253-257.29. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-RamosJ, O’Brien CF. Ropinirole for the treatment of early Parkinson’s disease. Neurology 1997;49:393-399.

930. Holt DA, Nauert GM, Othberg AI, Randall TS, Willing AE, Widen RH, Hauser RA, Sanberg PR,Olanow CW, Freeman TB. Infectious issues in human fetal neural transplantation. Cell Transplantation1997;6:553-556.31. Freeman TB, Vawter D, Goetz CG, Leaverton PE, Hauser RA, Sanberg PR, Godbold JH, OlanowCW. Toward the use of surgical placebo-controlled trials. Transplantation Proceedings1997;29:1925.32. Koller W, Pahwa R, Busenbark K, Hubble J, Wilkinson S, Lang A, Tuite P, Sime E, Lazano A,Hauser R, Malapira T, Smith D, Tarsy D, Miyawaki E, Norregaard T, Kormos T, Olanow CW. Highfrequencyunilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. AnnNeurol 1997; 292-299.33. Gold M, Hauser RA, Chen MF. Plasma thiamine deficiency associated with Alzheimer’s disease butnot Parkinson’s disease. Metabolic Brain Disease 1998;13:43-53.34. Hauser RA, Friedlander J, Smith DA, Nolan MF. Delayed stimulation-induced thalamic ataxiasyndrome. Neurology 1998:50:1184-1185.35. Kordower JH, Freeman TB, Chen EY, Mufson EJ, Sanberg PR, Hauser RA, Snow B, Olanow CW.Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson’s disease. MovementDisorders 1998;13:383-393.36. Hauser RA, Molho E, Shale H, Pedder S, Dorflinger EE, and the Tolcapone De Novo Study Group.A pilot evaluation of the tolerability, safety and efficacy of tolcapone alone, and in combination with oralselegiline, in untreated Parkinson’s disease patients. Movement Disorders 1998;13:643-647.37. Hauser RA, Malek AR, Rosen R. Successful treatment of a patient with severe refractory myastheniagravis using mycophenolate mofetil. Neurology 1998;51:912-913.38. Sethi KD, O’Brien CF, Hammerstad JP, Adler CH, Davis TL, Taylor RL, Sanchez-Ramos J, BertoniJM, Hauser RA. Ropinirole for the treatment of early Parkinson’s disease: a 12-month experience. ArchNeurol 1998;55:1211-1216.39. Adler CH, Singer C, O’Brien C, Hauser RA, Lew MF, Marek KL, Dorflinger E, Pedder S, DeptulaD, Yoo K. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinsondisease treated with levodopa-carbidopa. Arch Neurol 1998;55:1089-1095.40. Kompoliti K, Goetz CG, Boeve BF, Maraganore DM, Ahlskog JE, Marsden CD, Bhatia KP, GreenePE, Przedborski S, Seal EC, Burns RS, Hauser RA, Gauger LL, Factor SA, Molho ES, Riley DE.Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol1998;55:957-961.41. Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, Olanow CW. Long-termevaluation of bilateral fetal nigral transplantation in Parkinson’s disease. Arch Neurol 1999;56:179-187.42. Zesiewicz TA, Gold M, Chari G, Hauser RA. Current issues in depression in Parkinson’s disease.Am J Geriatr Psych 1999;7:110-118.

1043. Zesiewicz TA, Hauser RA. Ropinirole in the treatment of Parkinson’s disease. Expert Opinion onInvestigational Drugs 1999;8:697-710.44. Hauser RA, Zesiewicz TA. Management of early Parkinson’s disease. Medical Clinics of NorthAmerica 1999;83:393-414.45. Zesiewicz TA, Gold M, Chari G, Hauser RA. Depression and Anxiety in Parkinson’s Disease.American Journal of Geriatric Psychiatry. 1999;7:110-118.46. Freeman TB, Vawter DE, Leaverton PE, Godbold JH, Hauser RA, Goetz CG, Olanow CW. Use ofplacebo surgery in controlled trials of cellular-based therapy for Parkinson’s disease. NEJM 1999;341:988-992.47. Hauser RA, Wahba MN, Zesiewicz TA, McDowell Anderson W. Modafinil treatment ofpramipexole-associated somnolence. Mov Disord 2000;15:1269-1271.48. Olanow CW, Tasmar Advisory Panel (including Hauser RA). Tolcapone and hepatotoxic effects.Arch Neurol 2000:57;263-267.49. Zesiewicz TA, Hauser RA. Depression in patients with Parkinson's disease: epidemiology,pathophysiology and treatment options. CNS Drugs 2000;13:227-304.50. Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O’Brien CF, Molho ES, FactorSA. A home diary to assess functional status in Parkinson’s disease patients with motor fluctuations anddyskinesia. Journal of Clinical Neuropharmacology 2000;23:75-81.51. Zesiewicz TA, Helal M, Hauser RA. Sildenafil Citrate (Viagra) for the treatment of erectiledysfunction in men with Parkinson's disease. Movement Disorders 2000;15:305-308.52. Hauser RA, Freidlander J, Baker MJ, Thomas J, Zuckerman R. Adult Chediak-Higashi parkinsoniansyndrome with dystonia. Movement Disorders 2000; 15:705-708.53. Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow WC. Time course of loss ofclinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson'sdisease. Movement Disorders 2000;15:485-489.54. Freeman TB, Hauser RA, Sanberg PR, Saporta S. Neural transplantation for the treatment ofHuntington's disease. Progress in Brain Research 2000;127:405-11.55. Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence andepisodes of daytime sleep. Movement Disorders 2000;15:658-663.56. Freeman TB, Cicchetti F, Hauser RA, Deacon TW, Li XJ, Hersch SM, Nauert GM, Sanberg PR,Kordower JH, Saporta S, Isacson O. Transplanted fetal striatum in Huntington's disease: phenotypicdevelopment and lack of pathology. Proceedings of the National Academy of Sciences of the UnitedStates of America. 2000;97:13877-82.57. Freeman TB, Hauser RA, Sanberg PR, Saporta S. Neural transplantation for the treatment ofHuntington’s disease. Progress in Brain Research 2000;127:405-411.

1158. Freeman TB, Hauser RA, Willing AE, Zigova T, Sanberg PR, Saporta S. Transplantation of humanfetal striatal tissue in Huntington's disease: rationale for clinical studies. Novartis Foundation Symposium2000;231:129-138; discussion 139-147.59. Zesiewicz TA, Hauser RA. Depression in Parkinson’s Disease. CNS Drugs 2000.60. Hauser RA, Wahba MN, Zesiewicz TA, Anderson WM. Modafinil treatment of pramipexoleassociated somnolence. Movement Disorders 2000;15:1269-1271.61. Zesiewicz TA, Hauser RA. Neurosurgery for Parkinson's Disease. Seminars in Neurology2001;21:91-101.62. The Huntington Study Group (including Hauser RA). A randomized, placebo-controlled trial ofcoenzyme Q10 and remacemide in Huntington’s disease. Neurology 2001;57:397-404.63. Zesiewicz TA, Hauser RA. Phenomenology and treatment of tremor disorders. Neurologic Clin2001;19:3:651-680.64. Zesiewicz TA, Baker MJ, Dunne PB, Hauser RA. Diffuse Lewy Body Disease. Current TreatmentOptions in Neurology 2001;6:507-518.65. Parkinson Study Group (including Hauser RA). A randomized, controlled trial of remacemide formotor fluctuations in Parkinson's disease. Neurology 2001;56:455-462.66. Freeman TB, Willing A, Zigova T, Sanberg PR, Hauser RA. Neural transplantation in Parkinson’sdisease. Advances in Neurology 2001;86:435-445.67. Weiner WJ, Factor SA, Jankovic J, Hauser RA, Tetrud JW, Waters CH, Shulman LM, Glassman PM,Beck B, Paume D, Doyle C. The long-term safety and efficacy of pramipexole in advanced Parkinson’sdisease. Parkinsonism and Related Disorders 2001;7(2)115-120.68. Hauser RA, Burke D. Videotape demonstration of a sensory trick in writer’s cramp. MovementDisorders 2002;17:427.69. Zesiewicz TA, Hauser RA. Depression in Parkinson’s disease. Curr Psychiatry Rep 2002;4:69-73.70. Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, Scott D, Nauert GM, SoetyE, Sossi V, Holt A, Sanberg PR, Stoessl AJ, Freeman TB. Bilateral human fetal striatal transplantation inHuntington’s disease. Neurology 2002;58:687-695.71. Zesiewicz TA, Encarnacion E, Hauser RA. Management of essential tremor. Curr Neurol NeurosciRep 2002;2:324-330.72. Hauser RA, Holford NH. Quantitative description of loss of clinical benefit following withdrawal oflevodopa-carbidopa and bromocriptine in early Parkinson’s disease. Movement Disorders2002;17:(5)961-968.73. Zesiewicz TA, Borra S, Hauser RA. Clozapine withdrawal symptoms in a Parkinson’s diseasepatient. Movement Disorders 2002;17(6)1365-1367.

1274. Zesiewicz TA, Cimino CR, Malek AR, Gardner N, Leaverton PL, Dunne PB, Hauser RA. Drivingsafety in Parkinson’s disease. Neurology 2002;59:(11)1787-1788.75. Parkinson Study Group (including Hauser RA). A controlled trial of rasagiline in early ParkinsonDisease. Arch Neurol 2002;59:1937-1943.76. Zesiewicz TA, Baker MJ, Wahba M, Hauser RA. Autonomic nervous system dysfunction inParkinson’s disease. Curr Treat Options Neurol 2003;5:149-160.77. Zesiewicz TA, Hauser RA. Sleep attacks and dopamine agonists for Parkinson’s disease: What iscurrently known? CNS Drugs 2003;17:593-600.78. Whone AL, Warrs RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ,Remy P, Poewe WH, Hauser RA, Brooks DJ. Slower progression of Parkinson’s disease with ropiniroleversus levodopa: The REAL-PET study. Ann Neurol, July 2003,54(1)93-101.79. Crawford FC, Ait-Ghezala G, Morris M, Sutcliffe MJ, Hauser RA, Silver AA, Mullan MJ.Translocation breakpoint in two unrelared Tourette syndrome cases, within a region previously linked tothe disorder. Hum Genet 2003;113:154-161.80. Kase H, Aoyama S, Ichimura M, Ikeda K, Ishii A, Kanda T, Koga K, Koike N, Kurokawa M, KuwanaY, Mori A, Nakamura J, Nonaka H, Ochi M, Saki M, Shimada J, Shindou T, Shiozaki S, Suzuke F,Takeda M, Yanagawa K, Richardson PJ, Jenner P, Bedard P, Borrelli E, Hauser RA. Progress in pursuitof therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research anddevelopment toward a novel nondopaminergic therapy for Parkinson’s disease. Neurology 2003,61(Suppl 6):S97-100.81. Hauser RA, Hubble JP, Truong DD, Istradefylline US-001 Study Group. Randomized trial of theadenosine A 2A receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303.82. Zesiewicz TA, Carter SN, Sullivan KL, Staffeetti JS, Dunne PB, Hauser RA. Initial management ofParkinson’s disease in a Florida community. J Applied Research 2004;4:95-98.83. Adler CH, Hauser RA, Sethi K, Caviness JN, Marlor L, Anderson M, Hentz JG. Ropinirole forRestless Legs Syndrome: A Placebo-Controlled Crossover Trial. Neurology 2004;62:1405-1407.84. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM; Zydis Selegiline Study Group. Zydisselegiline reduces off time in Parkinson’s disease patients with motor fluctuations: A 3-month,randomized, placebo-controlled study. Movement Disorders 2004;19:426-432.85. Parkinson Study Group (including Hauser RA). A controlled, randomized, delayed-start study ofrasagiline in early parkinson disease. Arch Neurol 2004; 61; 561-566.86. Hauser RA. Levodopa/carbidopa/entacapone triple combination (Stalevo). Neurology 2004;62(Suppl1):S64-71.87. Zesiewicz TA, Strom JA, Borenstein AR, Hauser RA, Cimino CR, Fontanet H, Cintron C, StaffettiJF, Dunne PB, Sullivan KL. Heart failure in Parkinson's disease: analysis of the United States medicarecurrent beneficiary survey. Parkinsonism Relat Disord 2004;10:417-420.

1388. Zesiewicz TA, Louis ED, Sullivan KL, Menkin M, Dunne PB, Hauser RA. Substantial improvementin a Meige's syndrome patient with levetiracetam treatment. Movement Disorders 2004;19:1518-1521.89. Zesiewicz TA, Stamey W, Sullivan KL, Hauser RA. Botulinum toxin A for the treatment of cervicaldystonia. Expert Opin Pharmacother 2004;5:2017-2024.90. Pahwa R, Lyons K, Hauser RA. Ropinirole therapy for Parkinson’s disease. Expert Review ofNeurotherapeutics 2004;4:581-588.91. Sullivan KL, Hauser RA, Zesiwicz TA. Essential tremor. Epidemiology, diagnosis, and treatment.Neurologist 2004;10:250-258.92. Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, Olanow CW. Double-blind,randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. MovementDisorders 2004;19:916-923.93. Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: further validation and implicationsfor clinical trials. Movement Disorders 2004;19:1409-1413.94. Hauser RA, Lyons K. Future treatments for Parkinson’s disease. Neurol Clin 2004;22(Suppl):S149-166.95. Connors JJ 3rd, Sacks D, Furlan AJ, Selman WR, Russell EJ, Stieg PE, Hadley MN, Wojak JC,Koroshetz WJ, Heros RC, Strother CM, Duckwiler GR, Durham JD, Tomsick TO, Rosenwasser RH,McDougall CG, Haughton VM, Derdeyn CP, Wechsler LR, Hudgins PA, Alberts MJ, Raabe RD, GomezCR, Cawley CM 3rd, Krol KL, Futrell N, Hauser RA, Frank JI. Training, competency, and credentialingstandards for diagnostic cervicocerebral angiography, carotid stenting, and cerebrovascular intervention: ajoint statement from the American Academy of Neurology, the American Association of NeurologicalSurgeons, the American Society of Interventional and Therapeutic Neuroradiology, the American Societyof Neuroradiology, the Congress of Neurological Surgeons, the AANS/CNS Cerebrovascular Section,and the Society of Interventional Radiology. Neurology 2005;64:190-198.96. Zesiewicz TA, Hauser RA, Louis ED, Sullivan KL, Elble R, Dewey R, Ondo W, Rajput A, WeinerWJ. Practice Parameter: Therapies for essential tremor (an evidence based review). Report of the qualitystandards subcommittee of the American Academy of Neurology. Neurology (In Press).

14ABSTRACTS1. Brownson RH, Ridgeway SH, Hauser RA and Kline AW. Comparative cytoarchitecture of cerebralcortex in odontocetes with special emphasis on symmetry. Anat Rec 1984;20:24A.2. Brownson RH, Ridgeway SH, Hauser RA. Comparative cytoarchitecture of cerebral cortex inodontocetes with special emphasis on symmetry. Anat Rec 1985;211:27A.3. Brownson RH, Hauser RA. Comparative cytoarchitectonics of cerebral cortex in odontocetes withspecial emphasis on laterality and age. In: Proceedings of the XII International Anatomical Congress,London, 1985;A79.4. Hauser RA, Lacey MD, Knight MR. Hypertensive encephalopathy. MRI demonstration of reversiblecortical and white matter lesions. Neurology 1988;38(1):110.5. Hauser RA, Olanow CW. Oro-buccal dyskinesia associated with trihexyphenidyl therapy in a patientwith Parkinson’s disease. Movement Disorders 1990;6(3):211.6. Olanow CW, Woodward R, Hauser RA, et al. Central pharmacokinetics of levodopa + phenylalaninein a patient with advanced Parkinson’s disease. Neurology 1992;42(4):420.7. Korthals JK, Hauser RA, Olanow CW. Electromyographic studies on orthostatic tremor. MovementDisorders 1992;7(1):45.8. Hauser RA, Knisely SS. Reversible, non-enhancing MRI lesions in hypertensive encephalopathy.Journal of Neuroimaging 1993;3:76-77.9. Freeman TB, Hauser RA, Sanberg P, et al. Fetal transplantation in Parkinson’s disease. Neurology1994;44(Suppl 2):A324.10. Olanow CW, Koller WC, Hauser RA, et al. A prospective, longitudinal controlled study of deprenylin Parkinson’s disease. Neurology 1994;44(Suppl 2):A258.11. Hauser RA, Olanow CW, Koller WC. Time course of wash-out of symptomatic medication inParkinson’s disease. Neurology 1994;44(Suppl 2);A259.12. Hauser RA, Zesiewicz T, Olanow CW. Manganese overload may cause the clinical and magneticresonance imaging abnormalities of chronic liver disease. Movement Disorders 1994;9 (suppl 1):118.13. Freeman TB, Hauser RA, Sandberg OR, Borlongan CV, Snow BJ, Vingerhoets FJG, Smith DA,Olanow CW: Fetal tissue transplantation in Parksinon’s Disease. International BehaviorNeuroscience Society 1994; 3:2214. Freeman TB, Olanow CW, Hauser RA, et al. Fetal nigral transplantation into the postcommissuralputamen in Parkinson’s disease: The USF experience. Journal of Neurosurgery 1995;82:354A.

1629. Chari G, Hauser RA. Prolonged isolated limb dystonia as the initial manifestation of corticobasaldegeneration. Movement Disorders 1997;12:41.30. Smith DA, Hauser RA, Friedlander J, Malapira TJ, Nolan MF. Stimulation induced thalamic ataxiasyndrome. Neurology 1997;48:A432.31. Zesiewicz TA, Naidu KA, Baker M, Pedregal A, Prockop L, Hauser RA. Effect of amitriptyline,fluoxetine, and sertraline on dopamine concentration in rat striatum. Movement Disorders1997;12:840.32. Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O’Brien CF, Molho ES, FactorSA. Evaluation of a new home diary to assess functional status in Parkinson’s disease patients withfluctuations and dyskinesia. Movement Disorders 1997;12:843.33. Hauser RA, Zesiewicz TA, Friedlander J, Seeberger LC, O’Brien CF, Adler CH, Molho ES, FactorSA. Impact of different severities of dyskinesia on patient-defined functional status in Parkinson’sdisease. Movement Disorders 1997;12:843.34. Hauser RA, Anderson WMcD, Friedlander J, Zesiewicz TA, Gauger LL. Somnolence associatedwith pramipexole therapy in Parkinson’s disease. Movement Disorders 1997;12:845.35. Damiano AM, Willian MK, Burch G, Hauser R, Weiner W, Means E. Patient and caregiver healthrelatedquality-of-life questionnaires for Parkinson’s disease: self-administration versus telephoneinterview. Quality of Life Research 1998;7:585.36. Hauser RA, Stern MB, Olanow CW, Ferzola N, Azzaro A, Sharoky M. Tolerability and safety oftransdermal selegiline in mild to moderate Parkinson’s disease. Movement Disorders 1998;13(Suppl2):256.37. Brashear A, Truong D, Charles D, Comella C, Hauser RA, Tsui J, Botox Study Group, Branin MJ,Mordaunt J, Gibson J, Nordquist M, Stagg A, Jenkins S. A randomized double-blind, placebocontrolledstudy of intramuscular Botox for the treatment of cervical dystonia. Movement Disorders1998;13(Suppl 2):276.38. O’Brien C, Hauser RA, Sutton JP, Brashear A, Botox Study Group, Ripp K, Mourdant J, Bugarin D,Stagg A, Jenkins S. Evaluation of Botox manufactured from a new bulk toxin in the open labeltreatment of cervical dystonia. Movement Disorders 1998;13(Suppl 2):275.39. Zesiewicz TA, Hauser RA, Helal M. Sildenafil citrate (Viagra) for the treatment of erectiledysfunction in men with Parkinson’s disease. Neurology 1999;52(Suppl 2):A215-216.40. Wendell CM, Hauser RA, Nagaria MH, Sanchez-Ramos JR, Zesiewicz TA. Chief complaints ofpatients with Parkinson’s disease. Neurology 1999;52(Suppl 2):A90-91.41. Factor SA, Weiner WJ, Jankovic J, Hauser RA, Tetrud JW, Waters CH, Shulman LM, GlassmanPM, Besck B, Paume D, Doyle C, and the Pramipexole Study Group. Four year safety and adverseevents in an open-label experience of 306 patients on pramipexole for Parkinson’s disease. Neurology1999;52(Suppl 2):A407-408.

1742. 42. Weiner WJ, Factor SA, Jankovic J, Hauser RA, Tetrud JW, Waters CH, Shulman LM, GlassmanPM, Besck B, Paume D, Doyle C, and the Pramipexole Study Group. The long-term safety andefficacy of pramipexole in advanced Parkinson’s disease. Neurology 1999;52(Suppl 2):A261-262.43. Freeman T, Deacon T, Cicchette F, Hauser R, Sanberg P, Kordower JH, Saporta S, Isacson O.Histological evaluation of human fetal striatal transplants in a patient with Huntington’s disease.American Society for Neural Transplantation and Repair Abstracts 1999;56:21.44. Hauser RA, Comella C, Brashear A, Truong D, Charles PD, Tsui J, Botox 140-8051 Study Group,Mordaunt J, Nordquist M, Bugarin D. A randomized, multicenter, double-blind, placebo-controlledstudy of original Botox (botulinum type A) purified neurotoxin complex for the treatment of cervicaldystonia. Movement Disorders 1999; 56.45. Hauser RA, Stoessl JA, Eichler SR, Schwartz SW, Sanberg PR, Saporta S, Nauert M, Randall T,Hahn MA, Scott DL, Freeman TB. Pilot evaluation of human fetal striatal transplantation inHuntington disease. Neurology 2000; 54: (Suppl 3) S25.00246. Zesiewicz TA, Cimino CR, Gardner NM, Leaverton P, Hauser RA. Driving Safety in Parkinson’sDisease. Neurology 2000;54:S80.005.47. Hauser RA, Wahba MN, Zesiewicz TA Modafinil treatment of pramipexole-induced somnolence.Movement Disorders 2000;15:P680.48. Hauser RA, Reider C, Stacey M, Hubble J, Seeberger L, Williamson K, Dingmann C, Rice R,Krulewicz S, Zaninelli R. Acute versus gradual pramipexole to ropinirole switch. MovementDisorders 2000; 15: P681.49. Hauser RA, Watts RL, Freeman TB, Bakay RA, Ellias SA, Stoessl AJ, Eidelberg D, Dinsmore JH,Fink JS. A double-blind, randomized, controlled, multicenter clinical trial of the safety and efficacyof transplanted fetal porcine ventral mesencephalic cells versus imitation surgery in patients withParkinson’s disease. Movement Disorders 2001;16:983-984.50. Zesiewicz TA, Patel A, Cimino CR, Leaverton P, Staffeti JF, Hauser RA. Analysis of United StatesSocial Security disability insurance in Parkinson’s disease patient’s, 1999. Neurology 2001;56 (Suppl3): A101.51. Hubble J, Hauser RA, and the Kyowa 6002-US-001 Study Group. A novel adenosine antagonist(KW-6002) as a treatment for advanced parkinson’s disease with motor complications. Neurology2002;58(Suppl 3):A162.52. Hauser RA, Zesiewicz TA, Delgado HM, Gauger LL, Feldman NT. Evaluation and treatment offatigue in Parkinson’s disease. Neurology 2002;58 (Suppl 3):A433.53. Zesiewicz TA, Hauser RA, Graves AB, Cimino CR, Staffetti JF, Dunne PB, Sullivan KL. Heartfailure in elderly parkinson’s disease patient’s: analysis of United States Medicare data,1997- 1999. Neurology 2003;60 (Suppl 1): A83.54. Adler CH, Hauser RA, Sethi K, Caviness JN, Marlor L, Hentz GH. Ropinirole is beneficialfor restless legs syndrome: a placebo-controlled crossover trial. Neurology 2003;60(Suppl 1):A439-440.

55. Zhigao Z, de la Fuente-Fernandez, Hauser RA, Freeman TB, Olanow CW, Stoessl JADopaminergic alteration in Parkinson’s patients with off-period dyskinesia following striatalembryonic mesencephalic transplant. Neurology 2003;60 (Suppl 1): A126.18

19BOOK CHAPTERS1. Olanow CW, Hauser RA. The treatment of early Parkinson’s disease. In: Marsden CD and FahnS, eds. New Trends in Clinical Neurology; The Assessment and Therapy of Parkinsonism.England: Parthenon Publishing, 1990:77-88.2. Hauser RA, Olanow CW. Considerations in the design of clinical trials in Parkinson’s disease.In: Rose Clifford F, ed. Methodological Problems of Clinical Trials in Parkinson’s Disease.London: Smith-Gordon and Company, 1992:1-10.3. Hauser RA, Olanow CW. Designing clinical trials in Parkinson’s disease. In: Olanow CW,Lieberman, eds. The Scientific Basis for the Treatment of Parkinson’s Disease. London:Parthenon Publishers, 1992:275-293.4. Hauser RA, Olanow CW. Parkinson’s disease in the elderly. In: Barclay L, ed. Clinical GeriatricNeurology. Pennsylvania: Lea & Febiger 1993:155-169.5. Olanow CW, Hauser RA. Recent advances in Parkinson’s disease. In: Appel S, ed. CurrentNeurology. Illinois: Mosby-Year Book Inc. 1993;12:111-154.6. Olanow CW, Hauser RA. Neural transplants in the treatment of Parkinson’s disease and otherneurodegenerative disorders. In: Jankovic J, Tolosa, eds. Parkinson’s Disease and MovementDisorders. Maryland: Williams & Wilkins. 1993:549-568.7. Hauser RA, Olanow CW. Magnetic resonance imaging in neurodegenerative diseases. In: CalneDB, ed. Neurodegenerative Diseases. Pennsylvania: W.B. Saunders Co. 1994:445-469.8. Hauser RA, Freeman TB, Olanow CW. Surgical therapy for Parkinson’s disease. In: Kurlan R,ed. Treatment of Movement Disorders. New York: J.B. Lippencott Co. 1995:57-93.9. Freeman TB, Olanow CW, Hauser RA, Kordower JH, Holt DA, Borlongan CV, Sandberg PR.Human fetal tissue transplantation. In: Germano IM, ed. Neurosurgical Treatment of MovementDisorders. Park Ridge, Illinois: American Association of Neurological Surgeons 1998:177-192.10. Hauser RA, Olanow CW, Snow BJ, Freeman TB. Fetal nigral transplantation in Parkinson’sdisease: the USF pilot program (12- to 24-month evaluation). In Freeman TB, Widner H, eds.Cell Transplantation for Neurological Disorders: Toward Reconstruction of the Human CentralNervous System. Totowa, New Jersey: Humana Press Inc. 1998:19-30.11. Hauser RA, Freeman TB. Surgical therapy of Parkinson’s disease. In: Sawle G, ed. MovementDisorders in Clinical Practice. Isis Medical Media. 1999:57-71.12. Hauser RA, Zesiewicz TA. Management of Parkinson’s disease in the elderly. In: Meara J,Koller W, eds. Parkinson’s Disease and Parkinson’s Syndrome in the Elderly. United Kingdom:Cambridge University Press. 2000;134-164.

2013. Freeman TB, Hauser RA, Willing AE, Zigova T, Sanberg PR, Saporta S. Transplantation ofhuman fetal striatal tissue in Huntington’s disease: rationale for clinical studies. In: Neuraltransplantation in neurodegenerative disease: current status and new directions. West Sussex,England: John Wiley & Sons. (Novartis Foundation Symposium 231). 2000:129-144.14. Freeman TB, Hauser RA, Sanberg PR, Saporta S. Neural transplantation for the treatment ofHuntington’s disease. In: Dunnett SB, Bjorklund A, eds. Progress in Brain Research. ElsevierScience. 2000;127:405-411.15. Encarnacion EV, Hauser RA. Neural transplantation in Parkinson’s disease. In: Pahwa R, ed.Handbook of Parkinson’s Disease. Marcel Dekker, Inc. 2001:527-550.16. Zesiewicz TA, Hauser RA. Monoamine oxidase inhibitors. In Factor SA, Weiner WJ, eds.Parkinson's Disease: Diagnosis and Clinical Management. New York: Demos Press. 2002:365-378.17. Hauser RA, Zesiewicz T. Cell Transplantation. In: Pahwa R, Lyons K, eds. Therapy ofParkinson’s Disease, Third Edition. New York City: Marcel Dekker. 2004:343-351.18. Wahba M, Zesiewicz T, Hauser RA. Catechol-O-Methyltransferase Inhibitors in the Treatmentof Parkinson’s Disease. In: Ebadi M and Pfieffer R, eds. Parkinson’s Disease. Boca Raton,Florida: CRC Press. 2005:(55)705-712.19. Carlucci C, Hauser RA. Sleep apnea and Parkinson’s disease. In Pfeiffer R, ed. Parkinson’sDisease and Non-Motor Dysfunction. (In Press).20. Seeberger LC, Hauser RA. Cerebellar Tremor. In Lyons KE, Pahwa R, eds. Handbook ofEssential Tremor and Other Tremor Disorders. Taylor and Francis Group: Boca Raton, Florida,2005.

22Hauser RA, Sanberg PR, Freeman TB, Stoessl AJ. Bilateral human fetal striatal transplantation inHuntington’s disease. Neurology 2002;58:1704.RESPONSES TO LETTERSHauser RA, Wahba MN, Zesiewicz TA, Anderson WM. Modafinil and pramipexole-assoiatedsomnolence. Movement Disorders 2001;16:783-784.

23INTERNET PUBLICATIONSHauser RA. Cell Transplantation for the Treatment of Parkinson’s Disease. Awakenings.com 1997.Hauser RA, Hubble JP, Richardson E. Parkinson’s Disease. www.Neuroscience.com. Perspectives onCurrent Issues in Neurology and Psychiatry. No. 5, May 1999.Hauser RA, Pahwa R. Parkinson’s disease. www.emedicine.com. 2000.Hauser RA, Burke D. Essential Tremor. www.emedicine.com. 2000.Hauser RA, Wahba MN. Cosmetic use of Botulinum Toxin. www.emedicine.com. 2000Hauser RA. Neurotransplantation Strategies in Parkinson’s Disease. www.yourdoctor.com 2001Hauser RA, New Therapeutic Approaches for Parkinson’s Disease.www.medscape.com/viewarticle/477724 2004.INTERNET EDITORMovement Disorders Medical Editor for Neurology online textbook emedicine.com 2000-COMMUNITY PUBLICATIONSHauser RA. Botulinum toxin: a new treatment for spasticity. National Multiple Sclerosis Society.Outlook 1997; May/June:9-10.EDITORIAL BOARDMovement Disorders 1999-2004

24JOURNAL REVIEWERNeurologyMovement DisordersParkinsonism and Related DisordersJournal of NeuroimagingCell TransplantationJournal of Clinical NeuropharmacologyLancetClinical Pharmacology and TherapeuticsGRANT REVIEWERMedical Research Council (MRC) of the UKThe Wellcome TrustAWARDS AND HONORSClinician/Scholar of the Year, USF Department of Neurology, 1995/1996Faculty Scholar-Scientist Award, USF Department of Neurology 1998Phi Kappa Phi National Honor SocietyBeta Gamma Sigma National Honor SocietyBest Doctors in America 2001-2002Best Doctors in America 2002-2003Best Doctors in Amnerica 2003-2004Best Doctors in Amnerica 2004-2005SCIENTIFIC COMMENTATORWebMD 2000-Lancet 2000-

25NATIONAL AND INTERNATIONAL SCIENTIFIC PRESENTATIONS1. Hauser RA. Hypertensive Encephalopathy. MRI demonstration of reversible cortical and whitematter lesions. Poster Presentation. American Academy of Neurology 40 th Annual Meeting,Chicago, Illinois, April 1988.2. Hauser RA, Knisely SS. Reversible, non-enhancing MRI lesions in hypertensiveencephalopathy.Poster Presentation. American Society of Neuroimaging, 16 th Annual Meeting. Orlando, Florida,February 4, 1993.3. Hauser RA, Olanow CW, Koller WC. Time Course of Wash-out of Symptomatic Medication inParkinson’s Disease. Platform Presentation. American Academy of Neurology, 46 th AnnualMeeting, Washington D.C. May 3, 1994.4. Hauser RA, Zesiewicz T, Olanow CW. Manganese Overload May Cause the Clinical andMagnetic Resonance Imaging Abnormalities of Chronic Liver Disease. Poster Presentation. ThirdInternational Congress of Movement Disorders. Orlando, Florida. November 9, 1994.5. Hauser RA, Zesiewicz TA, Martinez C, Rosemurgy AS, Olanow CW. Manganese IntoxicationMay Cause Neurologic Dysfunction in Chronic Liver Disease. Poster Presentation. 47 th AnnualMeeting of the American Academy of Neurology. Seattle, Washington. May 11, 1995.6. Hauser RA, Freeman TB, Snow BJ, Sanberg PR, Nauert GM, Borlongan CV, Kordower JH,Olanow CW. Fetal nigral transplantation for Parkinson’s disease: 12 - 24 month evaluation.Platform presentation. American Society of Neural Transplantation, third annual conference.Clearwater, Florida, April 25, 1996.7. Hauser RA, Dorflinger E, Pedder S, Shimoun G, Yoo K, Molho E, Shale H, and the Tolcaponede Novo Study Group. Tolerability and efficacy of tolcapone (Tasmar) in untreated Parkinson’sDisease (PD). Poster Presentation. Fourth International Congress of Movement Disorders.Vienna, Austria, June 17-21, 1996.8. Hauser RA, Freeman TB, Gauger LL, Olanow CW. Fetal nigral transplantation for Parkinson’sDisease. Poster Presentation. Fourth International Congress of Movement Disorders. Vienna,Austria, June 17-21, 1996.9. Hauser RA, Freeman TB, Sanberg PR, Snow BJ, Nauert GM, Borlongan CV, Kordower JH,Olanow CW. Fetal nigral transplantation for Parkinson’s disease. Platform Presentation. ThirdInternational Congress of the Cell Transplant Society. Miami, FL, October 2, 1996.10. Chari G, Hauser RA. Prolonged isolated limb dystonia as the initial manifestation of corticobasaldegeneration. Poster Presentation. Third International Dystonia Symposium. Miami, FL, October11, 1996.11. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease.Poster Presentation. Tenth annual symposia on Etiology, Pathogenesis, and Prevention ofParkinson’s disease. Miami, FL, October 13, 1996.

2612. Smith DA, Hauser RA, Friedlander J, Malapira TJ, Nolan MF. Stimulation induced thalamicataxia syndrome. Poster Presentation. 49 th Annual Meeting of the American Academy ofNeurology. Boston, MA, April 17, 1997.13. Zesiewicz TA, Naidu KA, Baker M, Pedregal A, Prockop L, Hauser RA. Effect of amitriptyline,fluoxetine, and sertraline on dopamine concentration in rat striatum. Poster Presentation. EleventhAnnual Symposia on Etiology, Pathogenesis, and Prevention of Parkinson’s disease andHyperkinetic Movement Disorders. San Diego, CA, September 28, 1997.14. Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O’Brien CF, Molho ES,Factor SA. Evaluation of a new home diary to assess functional status in Parkinson’s diseasepatients with fluctuations and dyskinesia. Poster Presentation. Eleventh Annual Symposia onEtiology, Pathogenesis, and Prevention of Parkinson’s disease and Hyperkinetic MovementDisorders. San Diego, CA, September 28, 1997.15. Hauser RA, Zesiewicz TA, Friedlander J, Seeberger LC, O’Brien CF, Adler CH, Molho ES,Factor SA. Impact of different severities of dyskinesia on patient-defined functional status inParkinson’s disease. Poster Presentation. Eleventh Annual Symposia on Etiology, Pathogenesis,and Prevention of Parkinson’s disease and Hyperkinetic Movement Disorders. San Diego, CA,September 28, 1997.16. Hauser RA, Anderson WMcD, Friedlander J, Zesiewicz TA, Gauger LL. Somnolence associatedwith pramipexole therapy in Parkinson’s disease. Poster Presentation. Eleventh Annual Symposiaon Etiology, Pathogenesis, and Prevention of Parkinson’s disease and Hyperkinetic MovementDisorders. San Diego, CA, September 28, 1997.17. Hauser RA, Stern MB, Olanow CW, Ferzola N, Azzaro A, Sharoky M. Tolerability and safety oftransdermal selegiline in mild to moderate Parkinson’s disease. Movement Disorders1998;13(Suppl 2):256. Poster Presentation. Fifth International Congress of Movement Disorders.New York, NY. October 13, 1998.18. Wendell CM, Hauser RA, Nagaria MH, Sanchez-Ramos JR, Zesiewicz TA. Chief complaints ofpatients with Parkinson’s disease. Platform Presentation by Hauser RA. 51 st Annual Meeting ofthe American Academy of Neurology. Toronto, Ontario, Canada. April 20, 1999.19. Hauser RA, Stoessl JA, Eichler SR, Schwartz SW, Sanberg PR, Saporta S, Nauert M, Randall T,Hahn MA, Scott DL, Freeman TB. Pilot evaluation of human fetal striatal transplantation inHuntington disease. Platform Presentation by Hauser RA. 52 nd Annual Meeting of the AmericanAcademy of Neurology. San Diego, California. May 5, 2000.20. Hauser RA, Wahba MN, Zesiewicz TA. Modafinil treatment of pramipexole-inducedsomnolence. Poster Presentation by Hauser RA. 6 th International Congress of Parkinson’sDisease and Movement Disorders. Barcelona, Spain. June 3, 2000.21. Hauser RA, Reider C, Stacey M, Hubble J, Seeberger L, Gauger L, Williamson K, Dingmann C,Rice R, Krulewicz S, Zaninelli R. Acute versus gradual pramipexole to ropinirole switch. PosterPresentation by Hauser RA. 6 th International Congress of Parkinson’s Disease and MovementDisorders. Barcelona, Spain. June 3, 2000.

2722. Hauser RA, Watts RL, Freeman TB, Bakay RA, Stoessl AJ, Eidelberg D, Dinsmore JH, Fink JS.A double-blind, randomized, controlled, multicenter clinical trial of the safety and efficacy oftransplanted fetal porcine ventral mesencephalic cells versus imitation surgery in patients withParkinson’s disease. Platform Presentation by Hauser RA. Fifteenth Annual Symposia onEtiology, Pathogenesis, and Prevention of Parkinson’s disease and Hyperkinetic MovementDisorders. Chicago, Illinois. September 30, 2001.23. Hubble JP, Hauser RA, and the Kyowa 6002-US-001 Study Group. A novel adenosineantagonist (KW-6002) as a treatment for advanced parkinson’s disease with motor complications.Platform Presentation by Hauser RA. 54 th Annual meeting of the American Academy ofNeurology. Denver Colorado. April 16, 2002.24. Hauser RA, Zesiewicz TA, Delgado HM, Gauger LL, Feldman NT. Evaluation and treatment offatigue in Parkinson’s disease. Poster Presentation by Hauser RA. 54 th Annual meeting of theAmerican Academy of Neurology. Denver Colorado. April 18, 2002.25. Hauser RA and the Parkinson Study Group. Early treatment with rasagiline may attenuateprogression of Parkinson’s disease. Platform Presentation by Hauser RA. 6 TH Annual Congress ofthe European Federation of Neurological Societies. Vienna, Austria. October 27, 2002.26. Hauser RA. Medical management of Early Parkinson’s disease. 15 th annual scientificmeeting of the Hong Kong Neurological Society. Hong Kong. November 18 th 2002.27. Hauser RA. Medical management of Advance Parkinson’s disease. 15 th annual scientificmeeting of the Hong Kong Neurological Society. Hong Kong. November 18 th 2002.28. Hauser RA. The Role of Levodopa/carbidopa/entacapone Combination Treatment forParkinson’s Disease. Optimizing Levodopa Therapy. Seville, Spain. May 6, 2003.29. Hauser RA . Co-Chair (with Niall Quinn), Improving the Recognition of Wearing-off inParkinson’s Disease. Seville, Spain. May 7, 2003.30. Hauser RA. Practical Applications and Clinical Experience. Optimizing levodopatherapy: The role of COMT inhibition. EFNS Congress. Helsinki, Finland. Aug. 31,2003.31. Hauser RA. COMT Inhibitors in the Treatment of Parkinson’s Disease. MovementDisorder Society 8 th International Congress of Parkinson’s Disease and MovementDisorders. Rome, Italy. June 13, 2004.32. Hauser RA. Overview of Clinical Trials Aimed at Detecting Disease Progression inParkinson’s Disease. New Approaches to Neuroprotective Therapy in Parkinson’sDisease. Hamilton, Bermuda. August 20, 2004.33. Hauser RA. Does early treatment of Parkinson’s disease make a difference in the longterm? Platform presentation by Hauser RA. 8 th Congress of the European Federation ofNeurological Societies. Paris, France. September 5, 2004.

2834. Hauser RA. Stalevo in Daily Practice – when, where and how? Platform presentation byHauser RA. 8 th Congress of the European Federation of Neurological Sociaties. Paris,France. September 5, 2004.35. Hauser RA. Co-chairman, 2004 Wearing Off Working Group Meeting, Frankfurt,Germany. September 16-17, 2004.36. Hauser RA. Optimal use of a home diary in Parkinson’s disease clinical trials.Investigator Meeting Protocol 6002-EU-007. Montreux, Switzerland. October 1-2, 2004.

29NATIONAL COURSES TAUGHT1. Stroke: Etiology, Evaluation, Current and Future Therapies. American College of PhysiciansMKSAP VIII Review Course, Orlando, Florida, August 1990.2. Parkinson’s Disease: Update on Treatment. The American College of Physicians MKSAP VIIIReview Course, Orlando, Florida, August 1990.3. Magnetic Resonance Imaging of Parkinson’s Disease and Other Movement Disorders. AmericanSociety of Neuroimaging, 14 th Annual Meeting. Orlando, Florida. February 6, 1991.4. Neurology Review. MKSAP Annual Review Course. Orlando, Florida. August 1, 19935. Botulinum Toxin: Pharmacology Preparation & Side Effects. 57 th Annual Assembly of theAAPM&R Botulinum Toxin Workshop. Management of the Patient with Muscle Spasticity andRelated Movement Disorders. Marriott’s Orlando World Center. Orlando, Florida. November 20,19956. Botulinum Toxin: Management of Dystonias and Related Disorders. 57 th Annual Assembly of theAAPM&R Botulinum Toxin Workshop. Management of the Patient with Muscle Spasticity andRelated Movement Disorders. Marriott’s Orlando World Center. Orlando, Florida. November 20,1995.7. Case Presentations in Parkinson’s Disease. Kick-off dinner. 48 th Meeting of the AmericanAcademy of Neurology. San Francisco, California. March 23, 1996.8. Botulinum Toxin: Management of Dystonia and Spasticity. 20 th Annual Meeting of the AmericanSociety of Neuroimaging; Interventional Neuroimaging Seminar. San Juan, Peurto Rico. March8, 1997.9. Case Studies in Parkinson’s Disease. Kick-off Program. 50th Annual Meeting of the AmericanAcademy of Neurology. Minneapolis, Minnesota. March 26, 1998.

30NATIONAL AND INTERNATIONAL SEMINARS CHAIRED1. Co-Chair, The Millenium Lectures on Parkinson’s Disease. Miami, Florida. February 19, 2000.Dr. William Koller – Surgical Treatment of Parkinson’s DiseaseDr. Theresa Zesiewicz – Case Studies in Parkinson’s DiseaseDr. Abraham Lieberman – Use of COMT Inhibitors in Parkinson’s DiseaseDr. Robert A. Hauser – Dopamine Agonists in Parkinson’s DiseaseDr. William Weiner – Future Therapies in Parkinson’s Disease2. Chair, The Millennium Lectures on Parkinson’s Disease. Denver, Colorado. June 24, 2000.Dr. Rajesh Pahwa - Differential Diagnosis of Parkinson's DiseaseDr. Robert A. Hauser - Levodopa – The Gold Standard in Parkinson's DiseaseDr. Jean Hubble – Dopamine AgonistsDr. Robert A. Hauser – The Use of COMT Inhibitors in Parkinson's DiseaseDr. Rajesh Pahwa – Surgical Treatment of Parkinson's DiseaseDr. Jean Hubble – Video Case Studies – The Management of Parkinson's DiseaseDr. Peter LeWitt – Future Therapies for Parkinson's Disease3. Chair, The Millennium Lectures on Parkinson’s Disease. San Francisco, California.September 9, 2000.Dr. James Tetrud-Clues to the Etiology of Parkinson's diseaseDr. Robert A. Hauser-Levodopa: the Gold Standard in Parkinson's diseaseDr. Jean Hubble-Dopamine AgonistsDr. Robert A. Hauser-Use of COMT Inhibitors in Parkinson's diseaseDr. Rajesh Pahwa-Surgical Treatment of Parkinson's diseaseDr. Jean Hubble-The management of Parkinson's diseaseDr. Rajesh Pahwa-Differential Diagnosis of Parkinson's diseaseDr. James Tetrud-Future Therapies for Parkinson's disease4. Chair, The Millennium Lectures on Parkinson's Disease. Chicago, Illinois.October 7, 2000.Dr. Katie Kompoliti-Clues to the Etiology of Parkinson's diseaseDr. Robert A. Hauser-Levodopa-The Gold Standard in Parkinson's diseaseDr. Kathleen M. Shannon-Dopamine AgonistDr. Robert A. Hauser-Use of COMT Inhibitors in Parkinson's diseaseDr. Katie Kompoliti-Differential Diagnosis of Parkinson's diseaseDr. Kathleen M. Shannon-Surgical Treatment of Parkinson's diseaseDr. Un Kang-Future Therapies for Parkinson's disease

315. Chair, The Millennium Lectures on Parkinson’s Disease. New York City, New York.December 16, 2000.Dr. Jean Hubble-Clues to the Etiology of Parkinson’s DiseaseDr. Robert A. Hauser-Levodopa-The Gold Standard in Parkinsons DiseaseDr. Cheryl Waters-Dopamine AgonistsDr. Robert A. Hauser-Use of COMT Inhibitors in Parkinson’s DiseaseDr. Theresa Zesiewicz-Differential Diagnosis of Parkinson’s DiseaseDr. Richard Penn-Surgical Treatment of Parkinson’s DiseaseDr. Jean Hubble- The Management of Parkinson’s DiseaseDr. Cheryl Waters-Future Therapies for Parkinson’s Disease6. Chair, Advances in Managing Diseases of the CNS: Parkinson’s Disease. Charleston,South Carolina. November 2, 2002.Dr. David Riley – Etiology of Parkinson’s DiseaseDr. Robert A. Hauser – Medical Management of Parkinson’s DiseaseDr. Ali Rezai – Surgical Treatment of Parkinson’s Disease7. Co-Chair (with Raj Pahwa), Current Treatment Challenges and Emerging Therapies inParkinson’s Disease. Dallas, Texas. March 21, 2003.Dr. James Tetrud – Early Therapy for PDDr. Warren Olanow – Neuroprotection and disease modification in PDDr. Raj Pahwa – Motor Fluctuations and dyskinesiasDr. Michel Panisset – Freezing of gait in PDDr. Robert Hauser – Future Therapies for PDDr. Lawrence Elmer – Dementia and Cognitive Problems in PDDr. Jack Chen – Neuropsychiatric Problems in PDDr. Richard Dewey – Autonomic Dysfunction in PDDr. Tanya Simuni – Somnolence in PDDr. Mickie Welsh – Quality of Life in PD8. Co-Chair (with Niall Quinn), Improving the Recognition of Wearing-off in Parkinson’sDisease. Seville, Spain. May 7, 2003.Annette Bowron, MA – Wearing-off: The Patient’s PerspectiveDr. Kapil Sethi – Recognizing the Signs and Symptoms of Wearing-offDr. Fabrizio Stocchi – Linking the Pharmacology of Wearing-off to the symptomsDr. Mark Stacy – Identifying Wearing-off in Parkinson’s Disease: Comparison of apatient survey versus a programmed investigator evaluationDrs Robert Hauser and Naill Quinn – Interactive panel discussion on wearing-off:from identification to treatmentMary Baker MBE – The Role of the Patient Association

32OTHER NATIONAL PRESENTATIONSCorticobasal Degeneration presenting as Symmetric Progressive Apraxia without Parkinsonism.Presented at the Unusual Movement Disorders Seminar, 48 th Annual Meeting of the American Academyof Neurology. San Francisco, California. March 25,1996.Chediak-Higashi Young Adult Parkinsonian Syndrome. Presented at the Unusual Movement DisordersSeminar, 51 st Annual Meeting of the American Academy of Neurology. Toronto, Ontario, Canada. April19, 1999.Scientific Highlights – Movement Disorders (Neuroimaging), American Academy of Neurology.Platform presentation. 53 rd Annual Meeting of the American Academy of Neurology. Philadelphia,Pennsylvania. May 10, 2001.Scientific Highlights – Movement Disorders (Surgery, Sleep Disorders), American Academy ofNeurology. Platform Presentation. 54 th Annual Meeting of the American Academy of Neurology. DenverColorado. April 16, 2002.An Algorithm to…Publish An Algorithm. (Humorous Presentation). Platform Presentation. AnnualMeeting of the Parkinson Study Group. Coronado, California. May 18, 2002.

33Invited Speaker - National and International Presentations1. The Present and Future Management of Parkinson’s Disease. University of Texas Primary CareProgram. Dallas, Texas. December 7, 1991.2. Mechanisms of Cell Death in Parkinson’s Disease and Implications for Treatment. Grand Rounds,The Medical Center of Georgia- Mercer University School of Medicine. Macon, Georgia. July 8,1992.3. Implications of Oxidation Reactions in Parkinson’s Disease. Grand Rounds. Medical College ofVirginia. Richmond, Virginia. January 28, 1993.4. Present and Future Treatments for Parkinson’s Disease. Featured Speaker. Inaugural Meeting of theMovement Disorders Study Groups of Mexico. Zacatecas Mexico. February 23, 1996.5. Treatment of Parkinson’s Disease in the Long-term setting. 19 th Annual Symposium of the AmericanMedical Directors Association. New Orleans, Louisiana. March 7-8, 1996.6. Role of Dopamine agonists in the treatment of Parkinson’s disease. Workshop on the role ofselegiline in the treatment of Parkinson’s disease. Dana Point, California. May 4, 1997.7. Tremor Control Therapy Educational Symposium. Differential diagnosis of the tremor patient; Videocase studies of tremor types and results of deep brain stimulation; Basics of stimulator programming.Chicago, Illinois. May 30-31, 1997.8. Decision making for the long-term therapeutic management of patients with Parkinson’s disease.Conference on Current Perspectives on COMT Inhibition and Other Treatment Options forParkinson’s Disease. Vienna, VA. June 18, 1997.9. Tremor Control Therapy Educational Symposium. Differential diagnosis of the tremor patient;Medical management of tremor; Clinical results of multi-center studies of thalamic stimulation - theEuropean and North American safety and efficacy studies; Basics of stimulator programming; Videocase studies of tremor types and results of deep brain stimulation. Chicago, Illinois. July 26-27, 1997.10. New Solutions to Treating Parkinson’s Disease: a focus on long-term care. American Society ofConsultant Pharmacists (ASCP) 1997 Annual Meeting. November 13, 1997.11. Tremor Control Therapy Educational Symposium. Tremor and its Treatments; Video Workshop -Case studies of tremor types and results of deep brain stimulation. Chicago, Illinois. December 5,1997.12. The Changing Standard of Care in Parkinson’s Disease: the role of dopamine agonists and COMTinhibitors. Grand Rounds. University of North Carolina College of Medicine. Chapel Hill, NorthCarolina. January 22, 1998.13. New Medications and Their Role in the Treatment of Parkinson’s Disease. Memphis, Tennessee.March 19, 1998.

3414. Medical and Surgical Treatments for Tremor. Grand Rounds. University of Tennessee. Memphis,Tennessee. March 20, 1998.15. Botulinum toxin in the treatment of myofascial pain syndrome. New Horizons in Rheumatology.Indian River Plantation. Stuart, FL. June 12, 1998.16. Parkinson’s disease and COMT inhibition. Clinical trials in fluctuating patients. Roche speakersbureau educational symposium. Naples, Florida. June 12-14, 1988.17. COMT Inhibition for the Treatment of Parkinson’s Disease. XXXVI Congreso Argentino DeNeurologia. Corrientes, Argentina. September 26, 1998.18. Dopamine Agonists for the Treatment of Parkinson’s Disease. Grand Rounds. Vanderbilt University.Nashville, Tennessee. September 28, 1998.19. Medical therapy for Parkinson’s Disease. Grand Rounds. University of Alabama. Birmingham,Alabama. November 24, 1998.20. Entacapone for the Treatment of Parkinson's Disease. Consultant’s Meeting. Orlando, Florida. March25, 2000.21. Botulinum Toxin for the Treatment of Cervical Dystonia. Ask the Experts Series. 51 st AnnualMeeting of the American Academy of Neurology. Toronto, Ontario, Canada. April 21, 1999.22. Designing and Executing Clinical Trials in Parkinson’s Disease: a daylong seminar. Sponsored byQuintiles/ARC. Tampa, FL. June 18, 1999.23. Entacapone for the Treatment of Parkinson’s Disease. Neurology Consultant’s Training Seminar.Charleston, South Carolina. June 26, 1999.24. Parkinson’s Disease Consensus Summit. Practical Approahes to the Treatment of Parkinson’sDisease. San Juan, Peurto Rico. January 26-28, 2001.25. The Parkinson’s Disease Treatment Paradigm Shift. Grand Rounds. Boston University MedicalCenter. Boston, Massachusetts. June 5, 2001.26. Neuromodulation of Essential Tremor. Grand Rounds. Medical University of South Carolina.Charleston, South Carolina. August 2, 2001.27. Evaluation and Treatment of Parkinson’s Disease. Grand Rounds. Ohio State University. Columbus,Ohio. August 9, 2001.28. Dopamine Agonists as Early Treatment for Parkinson’s Disease. Grand Rounds. Columbia Veteran’sAdministration Hospital. Columbia, South Carolina. October 14, 2001.29. Continuous Dopaminergic Stimulation in Early Parkinson’s Disease. Quebec Association ofNeurology. Halifax, Nova Scotia. November 21, 2001.30. Contemporary Evaluation and Treatment of Parkinson’s Disease. Grand Rounds. Ottawa Hospital.Ottawa, Ontario. November 23, 2001.

3531. Medical Management of Early Parkinson’s Disease. 15 th Annual Scientific Meeting of the HongKong Neurological Society. Hong Kong. November 18, 2002.32. Medical Management of Advanced Parkinson’s Disease. 15 th Annual Scientific Meeting of the HongKong Neurological Society. Hong Kong. November 18, 2002.33. Continuous Dopaminergic Stimulation Hypothesis and its Implications for the Treatment ofParkinson’s Disease. Grand Rounds. University of Wisconsin. November 22, 2002.34. Triple Combination. Neuroscience Advisory Forum. Seville, Spain. May 5, 2003.

36INVITED SPEAKER - Other National and International Presentations1. Use of a home diary to assess functional status in Parkinson’s disease patients with motorfluctuations and dyskinesia. KW-6002 Investigator’s meeting. Atlanta, Georgia. March 8, 2002.2. Emerging Developments in PD: A current assessment of COMT inhibition. National Symposiumsponsored Novartis. Miami, Florida. April 5, 2002.3. Dopamine Agonists and Progression of Parkinson’s Disease. National Symposium sponsored byGlaxo-SmithKline. New York, New York. April 27, 2002.4. One Brain, Many Disorders. Diagnosis and Management of Parkinson’s Disease. NationalSymposium sponsored by the University of South Florida. Key West, Florida. May 10, 2002.5. One Brain, Many Disorders. Survey of Movement Disorders. National Symposium sponsored bythe University of South Florida. Key West, Florida. May 10, 2002.6. Use of a home diary to assess functional status in Parkinson’s disease patients with motorfluctuations and dyskinesia. Sarizotan Investigator’s meeting. Cancun, Mexico. May 11, 2002.7. Ropinirole to Slow Progression of Parkinson’s Disease. International Symposium sponsored byGlaxo-SmithKline. Malta. May 15, 2002.8. Ropinirole and Restless Legs Syndrome. International Symposium sponsored by Glaxo-SmithKline. Malta. May 16, 2002.9. Use of a home diary to assess functional status in Parkinson’s disease patients with motorfluctuations and dyskinesia. Sarizotan Investigator’s meeting. Bandol, France. May 27, 2002.10. Emerging Treatment Strategies in Parkinson’s Disease. National Symposium sponsored Novartis.Los Angeles, California. June 1, 2002.11. Update on COMT inhibition. National Symposium sponsored Novartis. Chicago, Illinois. June15, 2002.12. Use of the “Hauser” home diary in PD clinical trials. Sarizotan Investigator’s meeting. Rome,Italy. September 5, 2002.13. Use of the “Hauser” home diary in PD clinical trials. Spheramine Investigator’s meeting. NewYork, NY. October 15, 2002.14. Treatment of Early Parkinson’s Disease. The Keys to Neurology Series: Diagnosis andManagement of Abnormal Movements. National Symposium sponsored by Glaxo-SmithKline.Miami, Florida. October 19, 2002.15. Use of the “Hauser” home diary for clinical trials in advanced PD. NS233 Investigator’s meeting.Versailles, France. February 26, 2003.

3716. Levodopa/carbidopa/entacapone triple combination. New York, NY. February 28, 2003.17. The Role of Levodopa/carbidopa/entacapone Combination Treatment for Parkinson’s Disease.Optimizing Levodopa Therapy. International Symposium sponsored by Novartis and OrionPharma Neuroscience. Seville, Spain. May 6, 2003.

38INVITED SPEAKER - Regional Presentations1. Therapy of Parkinson’s Disease. Movement Disorders: Advances and Current Treatment.Annual Conference on Epilepsy, Orlando, Florida, June 8, 19892. Transplantation in Parkinson’s Disease. Movement Disorders: Advances and Current Treatment.Annual Conference on Epilepsy, Orlando, Florida, June 8, 19893. Update on Evaluation and Treatment of Parkinson’s Disease. Endocrine and NeurologicalDisorders: Implications for the Practice of Psychiatry. University of South Florida, Tampa,Florida, November 8, 19894. Update on Parkinson’s Disease and Other Movement Disorders. A Saturday Morning inPsychiatry. Tampa, Florida. March 24, 1990.5. Oxidation Reactions and the Management of Parkinson’s Disease. 12 th Annual Family PracticeReview. St. Petersburg, Florida. April 2, 1990.6. Parkinson’s Disease: New Frontiers. The Orlando Family Medicine Review Course. Orlando,Florida. July 3, 1990.7. The Current Management of Parkinson’s Disease. Pinellas Pharmacists Society, St. Petersburg,Florida, September 18, 1990.8. Overview of Parkinson’s Disease. Fitzgerald, Georgia, December 11, 1990.9. The Role of Eldepryl in the Management of Parkinson’s Disease. Medical Grand Rounds.Phoebe Putney Hospital. Albany, Georgia, December 12, 1990.10. Treatment Strategies for Parkinson’s Disease. Grand Rounds. Bay Medical Center, Panama City,Florida. January 15, 1991.11. Parkinson’s Disease: Clinical Assessment and Management. Tallahassee Physician’s AssistantsSociety, Tallahassee, Florida. January 15, 1991.12. New Directions in the Treatment of Parkinson’s Disease. Tampa Bay Pharmacist’s association.Memorial Hospital, Tampa, Florida. January 17, 1991.13. Emerging Treatment Strategies for Parkinson’s Disease. Florida Hospitals-Grand Rounds.Orlando, Florida. February 12, 1991.14. Parkinson’s Disease: Shortcomings of Current Management and New Directions for the Future.Cutsbert, Georgia. April 16, 1991.15. Does Selegiline Really Slow the Progression of Parkinson’s Disease? A Critical Appraisal.Jensen Beach, Florida. May 2, 1991.

3916. 16. Neuroprotective Strategies in Parkinson’s Disease. Grand Rounds, Sumter Hospital,Americus,Georgia. May 9, 1991.17. What’s Wrong with Current Therapy for Parkinson’s Disease ? Titusville, Florida. June 18, 1991.18. Where Do We Go from Here in the Treatment of Parkinson’s Disease? Salisbury, North Carolina.July 23, 1991.19. Making the Most of Current Therapies for Parkinson’s Disease. Grand Rounds, PiedmontMedical Center, Rock Hill, South Carolina. July 24, 1991.20. Primary Care of Parkinson’s Disease. Macon, Georgia. August 15, 1991.21. Parkinson’s Disease: Does Early Therapy Affect Outcome? Sebastion Summer Conference,Melbourne, Florida. August 23, 1991.22. Shortcomings of Parkinson’s Disease Management. Grand Rounds, Indian River MemorialHospital, Vero Beach, Florida. September 24, 1991.23. Parkinson’s Disease Seminar. Oxford, Mississippi, October 12, 1991.24. The Future of Parkinson’s Disease Management. Boynton Beach, Florida. October 30, 1991.25. Making the Most of Current Medications for Parkinson’s Disease. Grand Rounds, HighlandsRegional Medical Center, Sebring, Florida. December 5, 1991.26. Attempting to Understand Parkinson’s Disease and its Treatment. Moultrie, Georgia. January 14,1992.27. Optimizing Anti-Parkinsonian Therapy. Melbourne, Florida. January 23, 1992.28. Management Issues in Parkinson’s Disease. West Palm Beach, Florida. January 30, 1992.29. Research Directions in Parkinson’s Disease. Grand Rounds, West Volusia Hospital. Deland,Florida. February 6, 1992.30. Basic Management of Parkinson’s Disease. Florida State Physicians Assistants Annual MedicalConference. Jacksonville, Florida. February 23, 1992.31. Toward Better Management of Parkinson’s Disease. Grand Rounds, Martin Memorial Hospital.Stuart, Florida. March 10, 1992.32. Etiology, Diagnosis and Management of Parkinson’s Disease. Waycross, Georgia. April 2, 1992.33. Current Therapy for Parkinson’s Disease. Eleventh Annual Continuing Medical EducationProgram- Association of Philippine Physicians. Roanoke, VA. April 4, 1992.34. Update on Therapies for Parkinson’s Disease. Tifton, Georgia. April 9, 1992.

4035. Neuroprotective Therapy for Parkinson’s Disease. Grand Rounds, South Bay Hospital. Sun CityCenter, Florida. April 13, 1992.36. Pharmacotherapy for Parkinson’s Disease. Florida Pharmacists Association. Halifax Hospital.Daytona Beach, Florida. May 20, 1992.37. Slowing Progression of Parkinson’s Disease? Orlando, Florida. June 3, 1992.38. Research Frontiers in Parkinson’s Disease. Neurodegenerative Conference Series. HolmesRegional Medical Center/ Florida Institute of Technology. June 8, 1992.39. Inadequacies of Long-term Parkinson’s Disease Management. Implications for future Therapy.Grand Rounds, Lawnwood regional Medical Center. Fort Pierce, Florida. June 12, 1992.40. Delaying Disability in Parkinson’s Disease. Phillippine-American Medical Conference.Jacksonville, Florida. June 19, 1992.41. Current Strategies for Treating Parkinson’s Disease. Orlando, Florida. June 24, 1992.42. Levodopa Pharmacokinetics- Implications for Treating Parkinson’s Disease. Tallahassee, Florida.June 25, 1992.43. Symptomatic and Neuroprotective Therapy for Parkinson’s Disease. Greenville, SC. August 12,1992.44. Research Directions in Parkinson’s Disease. Greenville, SC. August 13, 1992.45. Medical and Surgical therapies for Parkinson’s Disease. Grand Rounds, Holmes RegionalMedical Center. Melbourne, Florida. August 21, 1992.46. Update on Parkinson’s Disease for the Nineties and Beyond. Saddlebrook, Florida. August 22,1992.47. Rational Strategies for Treating Parkinson’s Disease. Florida Osteopathic MedicalSociety.Daytona Beach, Florida. August 27, 1992.48. Neuroprotection, Trophic Factors, and Other Future Therapies for Parkinson’s Disease. BocaRaton, Florida. September 3, 1992.49. Improving Therapy for Parkinson’s Disease. Brookesville, Florida. September 17, 1992.50. 50. Advanced Treatment Strategies for Parkinson’s Disease. Johnson City, Tennessee.September 24,1992.51. Understanding Parkinson’s Disease Therapy. Grand Rounds, HCA Raulerson Hospital.Okeechobee, Florida. September, 30, 1992.52. Introduction to Medical Management to Parkinson’s Disease. Grand Rounds, Suncoast Hospital.Largo, Florida. October 1, 1992.

4153. Standard and Emerging Therapies for Parkinson’s Disease. Grand Rounds, The Medical Center ofCentral Georgia, Crisp County Hospital. Waycross, Georgia October 29, 1992.54. Emerging Strategies for the Treatment of Parkinson’s Disease. Grand Rounds, Southeast GeorgiaRegional Medical Center. October 20, 1992.55. Movement Disorders: Identification, Diagnosis and Treatment. Eleventh Annual ContinuingMedical Education Program, Crafts-Farrow State Hospital. Columbia S.C. November 5, 1992.56. Diagnosis and Treatment of Parkinson’s Disease. Parkinson’s Disease and Dystonia; and Update.Tampa, Florida. November 19, 1992.57. New Developments in the Treatment of Parkinson’s Disease. Fort Myers, Florida. November 10,1992.58. Oxidation and the Progression of Parkinson’s Disease. Deland, Florida. December 2, 1992.59. Advances in the Pathogenesis, Etiology and Treatment of Stroke. Islamic Medical AssociationAnnual Meeting. Tampa, Florida. January 23, 1993.60. Maximizing Long-term Therapy for Parkinson’s Disease. Grand Rounds, Humana Hospital.Crestview, Florida. January 26, 1993.61. Deprenyl as Neuroprotective Therapy. Orlando, Florida. February 11, 1993.62. Neuroprotective Therapy for Parkinson’s Disease - Implications of the DATATOP Study. GrandRounds, Roper Hospital. Charleston, South Carolina. February 16, 1993.63. Neuroprotective Therapy for Parkinson’s Disease - Implications of the DATATOP Study.64. Directors of Nursing Annual Meeting. Capital Healthcare. Tallahassee, Florida. February 17,1993.65. Understanding and Interpreting the DATATOP Study. Grand Rounds, Holmes RegionalMedical Center. Melbourne, Florida. February 19, 1993.66. Eldepryl and the DATATOP Study: Implications for Neuroprotective Therapy for Parkinson’sDisease. Stuart, Florida. February 26, 1993.67. The DATATOP Study: Neuroprotective versus Symptomatic Effects. Jacksonville, Florida.March 4, 1993.68. DATATOP and Parkinson’s Disease Management. Grand Rounds, Bay Medical Center.69. Panama City, Florida. March 9, 1993.69. Update on the Management of Parkinson’s Disease. Ocala, Florida. March 11, 1993.70. The Meaning of DATATOP. Lake Wales, Florida. March 12, 1993.71. Advances in Diagnosis and Management of Parkinson’s Disease. 37 th Annual Greenville Post

42Graduate Medical Seminar. Greenville, South Carolina. March 24, 1993.72. Medical and Surgical Therapy for Parkinson’s Disease. Grand Rounds, HCA Hospital. New PortRichey, Florida. March 22, 1993.73. Current Status of Neuroprotective Therapy for Parkinson’s Disease. Jacksonville, Florida. May20, 1993.74. Rethinking Parkinson’s Disease Management. Grand Rounds, University of Florida. Gainesville,Florida. June 8, 1993.75. Emerging Medical and Surgical Therapies for Parkinson’s Disease. Grand Rounds, HalifaxMedical Center. Daytona Beach, Florida. July 22, 1993.76. Current and Future Therapies for Parkinson’s Disease. Clearwater, Florida. August 5, 1993.77. Unusual Movement Disorders Video Seminar. Clearwater, Florida. September 2, 1993.78. Uncommon Problems and Management Strategies in Parkinson’s Disease. West Palm Beach,Florida. September 13, 1993.79. New Concepts in Stroke Diagnosis and Therapy. Annual Meeting of the Philippine MedicalAssociation. Orlando, Florida. October 22, 1993.80. Movement Disorders: Recognition, Diagnosis and Treatment. Florida Academy of FamilyPhysician 64 th Family Practice Weekend. Daytona Beach, Florida. November 19, 1993.81. Stroke Prevention. Orlando Health Center. Grand Rounds. Orlando, Florida. September 15,1994.82. Maximizing Stroke Therapy. Orlando, Florida. October 27, 1994.83. Medical and Surgical Advances in the Treatment of Parkinson’s Disease. Watson Clinic 39 thAnnual Spring Seminar. Lakeland, Florida. March 11, 1995.84. Mechanisms of Neuroprotection. Tarpon Springs, Florida. May 27, 1995.85. Taking Control of Parkinson’s Disease. A National Symposium for Patients, Caregivers andPhysicians. June 14, 1995. Local moderator, Hyatt Regency Tampa, Tampa, Florida.86. 86. Research Issue in Parkinson’s Disease. University of South Florida Biomedical AgingProgram.Tampa, Florida. November 9, 1995.87. Developments in new medications for Parkinson’s disease: dopamine agonists and COMTinhibitors. Tampa FL. December 14, 1997.88. New medications for Parkinson’s disease: dopamine agonists and COMT inhibitors. BirminghamAlabama. April 3, 1997.89. Therapy and Management of Parkinson’s Disease. Fort Myers, FL. April 25, 1997.

4390. New dopamine agonists and COMT inhibitors for the treatment of Parkinson’s disease. Sarasota,Florida. June 12, 1997.91. New medications for the treatment of Parkinson’s disease. Winston-Salem, North Carolina. June18, 1997.92. New medications for the treatment of Parkinson’s disease. Greensboro, North Carolina. June 19,1997.93. Thalamic Stimulation for Parkinson’s disease: what it can and cannot do. Saint Petersburg,Florida. June 21, 1997.94. New dopamine agonists and COMT inhibitors for the treatment of Parkinson’s disease. Orlando,FL. July 22, 1997.95. Dopamine agonists in the elderly Parkinson’s disease patient. Tallahassee, FL. October 30, 1997.The changing standard of care in Parkinson’s disease. Ft. Lauderdale, FL. November 6, 1997.96. New Dopamine agonists and COMT inhibitors. The role of new medications in the treatment ofParkinson’s disease. Grand Rounds, Holmes Regional Medical Center. Melbourne, FL. December19, 1997.97. Treatment controversies in the management of Parkinson’s disease. Orlando, FL. January 16,1998.98. New treatments for Parkinson’s disease. Ninth annual osteopathic winter seminar. St. Pete Beach.January 30, 1998.99. The role of COMT inhibitors in the treatment of Parkinson’s disease. Atlanta, Georgia.April 4,1998.100. New advances in the treatment of Parkinson’s disease. Grand Rounds. Florida Hospital. Orlando,Florida. April 9, 1998.101. Current treatment advances in Parkinson’s disease. Daytona Beach, FL. May 7, 1998.102. COMT inhibition for the treatment of Parkinson’s disease. Naples, FL. June 9, 1998.103. Dopamine agonists and COMT inhibitors in the treatment of Parkinson’s disease. Grand Rounds.Bayonet Point Hospital. July 16,1998.104. Long-term considerations in the treatment of Parkinson’s disease. Savannah, GA. July 23, 1998.105. COMT inhibition for the treatment of Parkinson’s disease. Clearwater, FL. September 22, 1998.106. New therapies for the treatment of Parkinson’s disease. Grand Rounds. Bradenton, FL. October 1,1998.

44107. Thalamic stimulation for the treatment of Parkinson’s and essential tremor. Tampa, FL. October1, 1998.108. Current therapies for Parkinson’s disease. Jacksonville, FL. October 5, 1998.109. Parkinson’s disease: etiology, phenomenology, and treatment. Baptist Medical Center. GrandRounds. Jacksonville, FL. October 6, 1998.110. Old and new dopamine agonists. Orlando, FL. October 16, 1998.111. New therapies for Parkinson’s disease. Coral Springs, FL. October 20, 1998.112. COMT inhibition for the treatment of Parkinson’s disease. Bradenton, FL. October 26, 1998.113. New therapies for Parkinson’s disease. Lakeland, FL. October 27, 1998.114. Medical therapy for Parkinson’s disease. Ocala, FL. November 18, 1998.115. The role of COMT inhibition in the treatment of Parkinson’s disease. Springhill, FL. December 1,1998.116. New dopamine agonists for Parkinson’s disease. Tampa, FL. December 2, 1998.117. Sinemet CR versus immediate release in the treatment of Parkinson’s disease. Tampa, FL.December 14, 1998.118. Botulinum toxin full day conference: Pharmacology, Preparation, and Side Effects; Managementof Dystonias and Related Disorders; Management of Spasticity; Injection Workshop. BaysMedical Society. Panama City, Florida. March 24,1999.119. Tolcapone and Hepatotoxicity. New Port Richey, Florida. April 27, 1999.120. The Future Direction of Parkinson’s Disease Research. Innisbrook, Florida. June 12, 1999.121. Dopamine Agonists in the Treatment of Parkinson’s disease: efficacy, usefulness, and sideeffects. NPF Annual Centers of Excellence Patient Coordinator Conference. Miami, Florida.August 28,1999.122. New Medications for Parkinson’s Disease. Port Charlotte, Florida. September 11, 1999.123. Dopamine Agonists: Dyskinesia and Somnolence. Naples, Florida. October 29, 1999.124. Improving Levodopa Pharmacokinetics. Tampa, Florida. December 1, 1999.125. Dopamine Agonists: Efficacy, Usefulness, and Side Effects. Saint Louis, Missouri. December 9,1999.126. Treatment of Parkinson’s Disease. USF Symposium. Long Boat Key, Florida. January 15, 2000.

45127. Initial Treatment of Parkinson’s Disease with Ropinirole Reduces Long-term Dyskinesia. Tampa,Florida. January 20, 2000.128. Diagnosis, Etiology, and Treatment of Parkinson’s Diease. Grand Rounds, Bay Pines VAMedical Center. Saint Petersberg, Florida. February 23, 2000.129. Treatment Issues in Parkinson’s Disease. Marco Island, Florida. June 2-4, 2000.130. Advances in Neurology and Parkinson's Disease. Naples, FL. July 15-16, 2000.131. Parkinson’s Disease. Neurology for the Non-Neurologist. The Bays Medical Society. PanamaCity, Florida. October 21, 2000.132. New Dopamine Agonists in Parkinson’s Disease. Fort Lauderdale, Florida. November 1, 2000.133. Advances in the Treatment of Parkinson’s Disease. Neurology Clinical Forum. Palm Beach,Florida. November 10-12, 2000.134. Paradigm Shift: The role of Dopamine Agonists in Early and Late Parkinson’s Disease. KansasCity, Missouri. December 6, 2000.135. Early Use of Dopamine Agonists in the Treatment of Parkinson’s Disease. Tampa, Florida,January 20, 2000.136. Paradigm Shift: The role of Dopamine Agonists in Early and Late Parkinson’s Disease. DesMoines, Iowa. March 17, 2001.137. COMT inhibition and Continuous Dopaminergic Stimulation. Jacksonville, Florida. March 21,2001.138. Ropinirole causes less dyskinesia than levodopa: 5-yr data. Oklahoma City, Oklahoma. April 19,2001.139. Scientific Rationale for Continuous Dopaminergic Stimulation. West Palm Beach, Florida. April24, 2001.140. Dopamine Agonists Cause Less Dyskinesia than Levodopa. May 2, 2001. Grand Rounds. SaintPetersburg General Hospital. Saint Petersburg, Florida.141. Parkinson’s Disease evaluation and management. Geriatric Medicine for the Primary CarePhysician Summer Conference. Orlando, FL. July 6, 2001.142. COMT therapy in the management of Parkinson’s Disease. Columbus, Ohio. August 8, 2001.143. Advances in Botulinum Toxin Treatment for Cervical Dystonia. Saint Petersburg, Florida.August 30, 2001.144. Dopamine Agonists as Early Treatment for Parkinson’s Disease. Naples, Florida. October 16,2001.

46145. Evaluation and Treatment of Parkinson’s Disease. Grand Rounds. Naples Community Hospital.Naples, Florida. October 17, 2001.146. Scientific Rationale for Continuous Dopaminergic Stimulation. Tampa, Florida. November 28,2001.147. Practicum in Neurology: Management decisions in the treatment of early Parkinson’s disease –levodopa versus dopamine agonists. Key Largo, Florida. February 9, 2002.148. Update on Medical Management of Parkinson’s Disease. Naples, Florida. March 18, 2002.149. Continuous dopaminergic stimulation and long-term motor complications in Parkinson’s Disease.Mirapex Regional Advisory Board. Palm Beach, Florida. March 23, 2002.150. Dopamine Agonists and Progression of Parkinson’s Disease. Sarasota, Florida. May 1, 2002.151. Dopamine Agonists and Progression of Parkinson’s Disease. Melbourne, Florida. May 23, 2002.152. Emerging Treatment Strategies in Parkinson’s Disease. Maitland, Florida. June 11, 2002.153. Emerging Role of Dopamine Agonists in the Treatment of Parkinson’s Disease. Boca Raton,Florida. June 13, 2002.154. COMT inhibitors and the Continuous Dopaminergic Stimulation hypothesis. Fort Myers, FL. July12, 2002.155. COMT inhibitors and the Continuous Dopaminergic Stimulation hypothesis. West Palm Beach,FL. July 13, 2002.156. Scientific Rationale for the Continuous Dopaminergic Stimulation hypothesis in PD. Sarasota,FL. August 1, 2002.157. Update on medical management of Parkinson’s disease. Fort Myers, FL. October 17, 2002.158. Optimizing the approach to early treatment of Parkinson’s disease. Advances in ManagingDiseases of the CNS. Charleston, SC. November 2, 2002.159. Medical Management of Parkinson’s Disease. Grand Rounds. St. Mary’s Hospital. Madison,Wisconsin. November 21, 2002.160. Medical Management of Parkinson’s Disease. An Update on Movement Disorders. Seminarsponsored by the University of Kansas. Kansas City, Missouri. December 14, 2002.OTHER NATIONAL TEACHING ACTIVITIESProfessor’s Rounds. Case Studies with residents. University of Wisconsin. Madison, Wisconsin.November 22, 2002.

47MODERATORSurgical therapies workshop. Parkinson Study Group. February 28, 1998.Co-Chair, Neurology Science Committee and Scientific Program Subcommittee Session S64, AmericanAcademy of Neurology 52 nd Annual Meeting, May 4, 2000.NATIONAL COMMUNITY LECTURES1. Research update on fetal transplantation for Huntington’s disease. Twelfth annual Huntington’sDisease Society of America convention. Rochester, New York. June 27, 1997.2. Fetal Cell Transplantation in Huntington’s Disease. Annual Convention of the Huntington’s DiseaseSociety of America. Orlando, Florida. June 9-11, 2000.REGIONAL COMMUNITY LECTURES1. The Physician’s Perspective on Parkinson’s Disease. Longboat Key Parkinson’s Disease SupportGroup. Longboat Key, Florida. January 25, 1991.2. Parkinson’s Disease - An Overview for Patients. Sarasota Parkinson’s disease Support Group.Sarasota, Florida. February 11, 1991.3. What Your Physician Should Know About Parkinson’s Disease. Sun City Parkinson’s DiseaseSupport Group. Sun City Center, Florida. February 19, 1991.4. What is Stroke? Positive Outcomes from Negative. Strokes Workshop, Tampa General HospitalRehabilitation Center. Tampa, Florida. February 21, 1991.5. What’s New in the Treatment of Parkinson’s disease? West Pasco Parkinson’s Disease SupportGroup. Hudson, Florida. April 4, 1991.6. Multiple Sclerosis- An Overview for Patients. Gulf Coast MS Chapter. Sheraton Grand Hotel,Tampa, Florida. May 18, 1991.7. New Therapies for Parkinson’s Disease. Suncoast Parkinsonians Support Group. St. Petersburg,Florida. September 9, 1991.8. How Anti-parkinsonian Medications Should Be Used. Hillsborough County Parkinson’s DiseaseSupport Group. Florida Mental Health Institute, Tampa, Florida. October 17, 1991.9. Effective Management of Parkinson’s Disease. West Pasco Parkinson’s Disease Support Group.New Port Richey. January 2, 1992.10. What is MS and How is it Treated? Florida Gulf Coast Chapter of the National Multiple SclerosisSociety. Newly Diagnosed Seminar. Tampa, Florida. January 8, 1992.

4811. Etiology, Diagnosis and Treatment of Parkinson’s Disease. Lakeland Parkinson’s Disease Supportgroup. Lakeland, Florida. February 12, 1992.12. Understanding Multiple Sclerosis and Its Management. Newly Diagnosed MS Support Group.Saint Joseph’s Hospital. Tampa, Florida. May 28, 1992.13. Advanced Treatment Strategies for Parkinson’s Disease. Manasota Parkinson’s Disease SupportGroup. Bradenton, Florida. November 9, 1992.14. New Developments in the Treatment of Parkinson’s Disease. Winter Park Civic Center. WinterHaven, Florida. November 13, 1992.15. Medical and Surgical Treatment of Parkinson’s Disease. WSUN Radio. Tampa Bay, Florida.February 10, 1993.16. Eldepryl and the DATATOP Study - What it Means for Patients with Parkinson’s Disease. FortMyers Parkinson’s Disease Support Group. Fort Myers, Florida. February 25, 1993.17. Eldepryl and the DATATOP Study - What it Means for Patients with Parkinson’s Disease. NorthPort Parkinson’s Disease Support Group. Port Charlotte, Florida. February 25, 1993.18. Advances in Diagnosis and Treatment of Parkinson’s Disease. St. Petersburg Parkinson’s DiseaseSupport Group. St. Petersburg, Florida. April 12, 1993.19. Movement Disorders: A Video Seminar. Tampa General Hospital. Tampa, Florida. November 4,1993.20. New Medical and Surgical Therapies for Parkinson’s Disease. Seventh Annual Parkinson’ sDisease Patient and Family Seminar. Holy Cross Hospital. Fort Lauderdale, Florida. November13, 1993.21. Botulinum Toxins for the Treatment of Dystonias. Tampa Bay National Spasmodic TorticollisAssociation Support Group Inaugural Meeting. Tampa, Florida. February 4, 1995.22. New Forms of Therapy for Parkinson’s Disease. West Coast Florida Parkinson’s Disease SupportGroup. University of South Florida, Tampa, Florida March 16, 1995.23. Status of Clinical Trials for Huntington’s Disease. Florida West Coast Huntington’s Disease SupportGroup. Tampa, Florida. September 17, 1995.24. Surgical Treatments for Parkinson’s Disease. Lee Memorial Health System. Parkinson’s Seminar forSupport Group. Ft. Myers, Florida. Novemeber 16, 1995.25. Update on Deprenyl. Suncoast Parkinson’s Support Group. St. Petersburg, FL February 12, 1996.26. New Dopamine Agonists and COMT inhibitors. TGH senior health series. Sun City Center, FlNovember 13, 1996.

4927. New Medications for Parkinson’s disease. Ocala Parkinson’s support group. Ocala, FL November 21,1996.28. New Dopamine agonists and COMT inhibitors for Parkinson’s Disease. Ruth Eckerd Hall,Clearwater, FL. January 9, 1997.29. Essential Tremor: current treatments and surgical options. Hauser R, Hallet M. Hosted by theInternational Tremor Foundation. MacInnes Auditorium, Tampa, FL. January 11, 1997.30. New Medications for Parkinson’s disease. Lake County Parkinson’s Support Group. Leesburg, FL.January 14, 1997.31. New Therapies for Spasticity: Medications, Botulinum Toxin, and Intrathecal Baclofen. NationalMultiple Sclerosis Society, Florida Gulf Coast Chapter. Tampa, FL. April 22, 1997.32. New Medications and Strategies for the Treatment of Parkinson’s disease. Leesburg Parkinson’sSupport Group. Leesburg, FL. January 13, 1998.33. Parkinson’s Disease: Meeting the Challenge. National Parkinson Foundation. Clearwater, Florida.January 29,1998.34. Parkinson’s Disease: Meeting the Challenge. Orlando, Florida. February 24, 1998.35. Medical Therapy for Parkinson’s Disease. Tampa General Hospital Sun City Seniors Health Series.March 4, 1998.36. Parkinson’s Disease. Aging Successfully Lecture Series. Ruth Eckard Hall. Clearwater, Florida.March 3, 1998.37. COMT inhibitors: new medications for the treatment of Parkinson’s disease. Bradenton Parkinson’sdisease support group. Bradenton, Florida. June 15, 1998.38. USF mini-med school: Parkinson’s Disease. Sun City Center. March 2, 1999.39. Medical and Surgical Treatment of Parkinson’s disease. American Parkinson’s Disease Associationsupport group. Clearwater, Florida. October 14, 1999.40. Medical and Surgical Treatment of Parkinson’s disease. American Parkinson’s Disease Associationsupport group. Lakeland, Florida. November 10, 1999.41. Dopamine Agonists: Dyskinesia and Somnolence. West Pasco PD support group. Port Richey,Florida. January 6, 2000.42. Current Research in Huntington’s Disease. Huntington’s Disease Support Group. Tampa, Florida.January 6, 2000.43. New Medications for Parkinson’s Disease. Sarasota, Florida. January 8, 2000.44. Towards Neuroprotection for Parkinson’s Disease. Leesburg, Florida. February 8, 2000.

5045. Current and Future Treatments for Parkinson’s Disease. Orlando, Florida. February 12, 2000.46. Diagnosis Parkinson’s Disease: What happens now? Young Parkinson’s Symposium. SaintPetersburg, Florida. February 24, 2001.47. New Management Strategies in Parkinson’s Disease. Springhill Support Group. Springhill, Florida.September 4, 2001.48. Diagnosis and Management of Parkinson’s Disease. East Pasco Support Group. January 16, 200249. New Developments in the Treatment of Parkinson’s Disease. Inverness Support Group. February 5,200250. New Developments in the Treatment of Parkinson’s Disease. Lake County Parkinson’s SupportGroup. February 9, 2002.51. Night School for the Brain. Parkinson’s Disease: From Diagnosis to Surgical Therapies to CellTransplantation. Diagnosis and Medical Management of Parkinson’s Disease. Tampa GeneralHealthcare. February 20, 2002.52. Update on Diagnosis and Treatment of Parkinson’s Disease. Daytona Beach, Florida. February 6,2003.53. Changing Treatment Strategies in Parkinson’s Disease. Brooksville, Florida. March 4, 2003.

51Regional Courses and Seminars DirectedHauser RA. Course Director: Neurology in the New Millenium 2003. Lecture: MedicalManagement of Parkinson’s Disease. April 13, 2002. Tampa FL.Hauser RA. Update on the medical management of Parkinson’s disease. Third AnnualAdvances in Managing Diseases of the Central Nervous System: Multiple Sclerosis andParkinson’s Disease. USF COM Activity.November 2-3, 2002. Charleston, South Carolina.Hauser RA. Course Director: Neurology in the New Millenium 2003. Lecture: MedicalManagement of Parkinson’s Disease. April 26, 2003. Tampa FL.Hauser RA. Update on the medical management of Parkinson’s disease. Third AnnualAdvances in Managing Diseases of the Central Nervous System: Multiple Sclerosis andParkinson’s Disease. USF COM Activity.November 8-9, 2003. Ashville, North Carolina.Hauser RA. Course Director: Neurology in the New Millenium 2004. Lecture: MedicalManagement of Parkinson’s Disease. October 30, 2004. Tampa FL.Hauser RA. Update on the medical management of Parkinson’s disease. Third AnnualAdvances in Managing Diseases of the Central Nervous System: Multiple Sclerosis andParkinson’s Disease. USF COM Activity.November 13-14, 2004. White Sulfur Springs, West Virginia.Director, Parkinson’s Disease Seminar for Patients and Caregivers. In association with Tampa GeneralHospital and the University of South Florida. Tampa General Hospital. Tampa, Florida. December 3,1994.Dr. Theresa Zesiewicz - Overview of Parkinson’s DiseaseDr. Robert Hauser - Advances in Medical Therapy for Parkinson’s DiseaseDr. Thomas Freeman - Fetal Transplantation for Parkinson’s DiseaseDr. Donald Smith - Thalamic Stimulation for Tremor282 in attendanceDirector, Spasticity Seminar for Patients and Caregivers. In association with Tampa General Healthcareand the University of South Florida. Tampa General Hospital. Tampa, Florida.December 7, 1996.Dr. Susan Alden - Pathophysiology of SpasticityDr. Robert Hauser - Management of Spasticity with Botulinum Toxin injectionsPam Martin, RN - Management of Spasticity with Intrathecal BaclofenKathleen Albany, PT, MPH - Physical Therapy Interventions for Spasticity

52Director, Parkinson’s Disease Seminar for Patients and Caregivers. In association with TampaGeneral Healthcare and the University of South Florida. College of Public Health. Tampa, Florida. March14, 1998.Dr. Juan Sanchez-Ramos - Clues to the Etiology of Parkinson’s DiseaseDr. Robert Hauser - Medical Management of Parkinson’s DiseaseDr. Theresa Zesiewicz - Treatment of Secondary Symptoms of Parkinson’s DiseaseDr. Fernando Valle - Pallidotomy for Parkinson’s DiseaseDr. Donald Smith - Stimulation Surgeries for Parkinson’s DiseaseDr. Thomas Freeman - Cell Transplantation Strategies for Parkinson’s Disease400 in attendanceDirector, Parkinson’s Disease Seminar for Patients and Caregivers. In association with TampaGeneral Healthcare and the University of South Florida. College of Public Health. Tampa, Florida. March23, 1999.Dr. Theresa Zesiewicz – Overview of Parkinson’s DiseaseDr. Juan Sanchez-Ramos - Clues to the Etiology of Parkinson’sDiseaseDr. Robert Hauser - Medical Management of Parkinson’s DiseaseDr. Fernando Valle - Pallidotomy for Parkinson’s DiseaseDr. Donald Smith - Stimulation Surgeries for Parkinson’s DiseaseDr. Thomas Freeman - Cell Transplantation Strategies for Parkinson’s Disease350 in attendanceDirector, Neurology in the New Millennium 2003. Tampa, Florida. April 26, 2003.Dr. William Tatum – Pharmacotherapy for EpilepsyDr. Selim Benbadis – When Drugs Fail to Control Seizures: Non-pharmacologic OptionsDr. Robert Hauser - Management of Parkinson’s Disease 2003.Dr. Maria-Carmen Wilson – Management of the Intractable Headache PatientDr. Peter Dunne – Multiple Sclerosis: Symptoms and Primary Disease ManagementDr. Carolyn Geis – Evaluation and Management of Spasticity: Focus on BotulinumToxinDr. Michael Hoffman – Advances in Stroke and Cerebrovascular DiseaseDirector, Neurology in the New Millennium 2004, Tampa, Florida. October 30, 2004Dr. William Tatum – Epilepsy: Matching the Medicine to the PatientDr. Selim Benbadis – Approach to Medically Refractory Seizures: “When Drugs Fail”Dr. Amanda G. Smith – Diagnosis and Management of DementiaDr. Carolyn Geis – Treatment of Post-Stroke Spasticity with Botulinum ToxinDr. Robert Hauser – Medical Management of Parkinson’s Disease: 2004Dr. Fernando Vale – Surgery for Parkinson’s DiseaseDr. B. Ashok Raj – Treatment of DepressionDr. Peter Dunne – Multiple Sclerosis – Advances in Disease and Symptom TreatmentDr. Michael W. Hoffman – The Multifaceted Advances in Cerebral Vascular DiseaseDr. Charles W. Brock – Neuropathic Pain

53SELECTED INTRAMURAL PRESENTATIONS1. Introduction to Laboratory Tests in Neurology. Department of Neurology New Resident Orientation.July 1, 1999.2. Parkinson’s Disease Supertalk: Etiology, epidemiology, and treatment. (2 hrs). Department ofNeurology Grand Rounds. September 23, 1999.3. Lessons from DATATOP. Neurology Resident Journal Club. October 28, 1999.4. Parkinson’s Disease: The big picture. Neurology Interest Group. 1 st -4 th Year Medical Students. (2hrs.) November 1, 1999.5. Dopamine Agonists versus Levodopa in the Treatment of Parkinson’s Disease: Dyskinesias andSomnolence. Department of Pharmacology Grand Rounds. November 9, 1999.6. Parkinson’s Disease in an Aging Population. Biomedical Aging Course. November 30, 1999.7. Phenomenology and Treatment of Tremor. Department of Neurology Grand Rounds. December 2,1999.8. COMT Inhibitors in the Treatment of Parkinson’s Disease. Department of Neurology Grand Rounds.March 23, 2000.9. Parkinson’s Disease Clinical Correlation: From Neuroscience to Clinical Care. Course Director: Dr.Nolan, Department of Anatomy. April 13, 2000.10. Scientific and Societal Issues Regarding Parkinson’s Disease. Biomedical Aging Course. CourseDirector: Dr. David Morgan., Department of Pharmacology. November 29, 2001.

54TELECONFERENCESRational Use of Combination Therapy for Parkinson’s Disease. A Group discussion for Neurologists.May 19, 1994October 3, 1994October 19, 1994October 25, 1994November 15, 1994April 26, 1995Treatment Strategies in Parkinson’s Disease. A Seminar for Primary Care Physicians.June 6, 1994 February 21, 1995 October 3, 1995June 8, 1994 April 3, 1995 October 4. 1995June 9, 1994 April 4, 1995 October 16, 1995August 2, 1994 April 5, 1995 October 17, 1995August 4, 1994 May 22, 1995 October 18, 1995September 6, 1994 May 24, 1995 November 13, 1995September 7, 1994 August 21, 1995 November 15, 1995September 8, 1994 August 22, 1995 December 13, 1995October 4, 1994 August 23, 1995 December 18, 1995October 5, 1994 August 28, 1995 December 19, 1995November 29, 1994 August 29, 1995 December 20, 1995November 30, 1994 August 31, 1995 December 21, 1995July 18, 1994 October 2, 1995New medications for Parkinson’s disease: Dopamine agonists and COMT inhibitors. April 4, 1997.

55Tolcapone (Tasmar) for the treatment of Parkinson’s disease (Roche):September 29, 1998October 22,1998October 23,1998December 15, 1998Neuroprotection in Parkinson’s disease3/22/99Tolcapone and Hepatotoxicity5/6/996/24/997/1/99Essential Tremor Teleconference7/6/997/7/99Entacapone and Continuous Dopaminergic Stimulation10/16/2001Levodopa/carbidopa/entacapone Combination Therapy04/15/03Clinical Update on modafinil (Provigil)04/15/0304/24/0304/30/0305/20/0305/27/0305/29/0306/10/0306/18/0306/30/0307/15/03

56MEDIA APPEARANCES1. WTMT channel 32, “Senior Connections” television interview. Signs and symptoms of Parkinson’sdisease. October 4, 1994.2. WTMP radio interview. Parkinson’s disease - New treatments and advances. November 17, 19943. WFLA channel 8 television interview. Chronic thalamic stimulation for tremor. December 9, 1994.4. NBC TV national news affiliates, WFLA channel 8. Tolcapone clinical trials in Parkinson’s disease.February 13, 1995.5. WFLA channel 8 television interview. New treatments and clinical trials for Parkinson’s disease. June14, 1995.6. WTVT channel 13 television interview. “Good Morning Tampa Bay.” Janet Reno and Parkinson’sdisease. November 22, 1995.7. America’s Health Network (national cable network - two hour live interview and patient calls).Parkinson’s disease. November 17, 1996.8. CITV local cable channel 20. Parkinson’s Disease. Half hour interview. February 3, 7, 10, 14, 17,1998.9. Healthcare, Medicare, and You. Parkinson’s Disease. WBSV. Sarasota, Florida. February 23, 1998.10. Huntington’s disease cell transplantation. Bay News Nine. June 23, 1998.11. Deep brain stimulation for the treatment of Parkinson’s disease. WFLA channel 8 televisioninterview. November 17, 1998.12. Parkinson’s disease in young adults (Michael J. Fox). Channel 28 television interview. December 17,1998.13. Botulinum toxin therapy. Channel 13 (Fox News). March 1, 1999.14. Parkinson’s disease research. Good Day Tampa Bay. Channel 13 (Fox) interview. March 16, 1999.15. Neurotransplantation for Parkinson’s disease. Channel 28 (ABC) interview. March 17, 1999.16. Parkinson’s Disease. Towards a Cure. Healthtalk Interview. KNOT Radio. Prescott, Arizona.February 7, 2000.17. Parkinson's Disease Questions and Answers. Radio Interview. WDIS Boston, Massachusetts. June29, 200018. Parkinson’s Disease Questions and Answers. Radio Interview. WSAR Sommerset, Massachusetts.June 30, 2000.

5719. Parkinson's Disease Study Drug, Rasagiline, Question and Answers. Bay News 9, Tampa, FL.August 24,200120. Parkinson’s Disease Questions and Answers. Television Interview. WTBS Channel 10, Tampa, FL.September 4, 200121. Parkinson’s Disease Questions and Answers. Television Interview, Modern Medicine. Channel 67,New Port Ritchey, FL. September 26, 2001.22. Parkinson's Disease Questions and Answers. The Tampa Tribune, Tampa, FL October 3, 200123. Parkinson’s Disease – Slowing disease progression – Channel 8, Tampa, FL March 11, 200224. Retinal Cell Transplantation – Fox 13, Tampa, FL April 2, 200225. Retinal Cell Transplantation – Channel 28 Tampa, FL April 3, 200226. Florida Coalition to Cure Parkinson’s Disease – Channel 13, Tampa, FL April 12, 200227. Florida Coalition to Cure Parkinson’s Disease – St. Pete Times (Newspaper), April 12, 200228. Florida Coalition to Cure Parkinson’s Disease – WUSF, Tampa, FL April 12, 200229. Florida Coalition to Cure Parkinson’s Disease – Channel 8, Tampa, FL April 12,200230. Florida Coalition to Cure Parkinson’s Disease – Bay News 9 , Tampa, FL April 12,200231. Coenzyme Q10 – television interview with Linda Hurtado, local ABC affiliate. October 15, 200232. The future of Parkinson’s Disease (Florida COALITION to Cure Parkinson’s Disease) - radiointerview. WUSF FM. April 15, 200333. Challenges of Treating Parkinson’s Disease (Florida COALITION to Cure Parkinson’s Disease) –television interview. Fox 13 with Frank Robertson. April 25, 2003.34. Parkinson’s Disease: Symptoms and Treatment. Radio Interview. WLVU 1040 AM. April 26, 200334. The future of Parkinson’s Disease (Florida COALITION to Cure Parkinson’s Disease) - radiointerview. WUSF FM. April 15, 200335. The future of Parkinson’s Disease (Florida COALITION to Cure Parkinson’s Disease) – televisioninterview. BayNews 9. April 26, 2003.36. Possible bad case of Botox in West Palm Beach – Fox 13 News. November 30, 2004.

58MULTI-CENTER STUDY PARTICIPATION“A Double-blind Study of Two Dose Levels of CQA 206-291 Versus Placebo in the Treatment ofParkinson’s Disease” Sandoz (1990-1991)Co-Investigator“A Triple-Blind, Randomized Parallel Study Comparing Sinemet CR (50/200) with Sinemet 25/100 inParkinson’s Disease for Patients on No Prior Levodopa Therapy”Merck, Sharp and Dohme (1989-1995 )Investigator“Prospective Single-Blind, Double-Observer, Randomized Study Comparing Treatment with LevodopaPlus Deprenyl, Levodopa Plus Deprenyl Placebo, Parlodel Plus Deprenyl and Parlodel Plus DeprenylPlacebo in Patients with Parkinson’s Disease” (1989-1994)Investigator“Determination of the Dose Response and Plasma Concentration Response of Lazabemide (RO19-6327)In Delaying Time Until Treatment with Levodopa/Carbidopa is Required in Parkinson’s Disease Patients”Hoffmann-La Roche (Parkinson Study Group) (1992-1994)Investigator“A Phase II-III Prospective, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Safety andEfficacy Study of Recombinant, Human Ciliary Neurotrophic Factor (rHCNTF) in Patients withAmyotrophic Lateral Sclerosis”Regeneron (1992-1994)Investigator“Ropinirole Versus Placebo as an Adjunct to Levodopa in the Treatment of Parkinson’s Disease”SmithKline Beecham (1993- 1996)Investigator“Double-Blind, Placebo-Controlled, Parallel-group Comparison to Assess the Safety, Tolerance, andEfficacy of Pramipexole in Early Parkinson’s Disease (Part I) and to Assess Long Term Safety withOpen-Label Pramipexole (Part II)”UpJohn Laboratories (1993- 1999)Investigator“Double-Blind, Placebo-Controlled, Parallel-group Comparison to Assess the Safety, Tolerance, andEfficacy of Pramipexole in Advanced Parkinson’s Disease (0679) and to Assess Long Term Safety withOpen-Label Pramipexole (0979)”Boehringer Ingelheim (1993- 1997)Investigator“Clinical Investigation of Deep Brain Stimulation for Treatment of Tremor Using the Medtronic Model3382 DBS Lead and Itrell II System”Medtronics (1993-2000)Investigator“Parallel Group, Placebo-controlled, Dose-response, Tolerability, Safety and Efficacy Study ofPramipexole in Early Parkinson’s Disease (STEP-UP)”

59Upjohn (Parkinson Study Group) (1994- 1995)Investigator“Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism (DATATOP ExtensionStudies)”National Institutes of Health/University of Rochester/Somerset Pharmaceuticals (1993-1995)Investigator“A Pilot Evaluation of the Tolerability, Safety and Efficacy of Tolcapone alone, and in combination withSelegiline in Untreated Parkinson’s Disease Patients”Hoffmann-La Roche (1995)Investigator“A Double-Blind, Placebo-Controlled, Parallel Groups, Multicenter Evaluation of the MarketingFormulation of Tolcapone When Given Together with Sinemet (levodopa/carbidopa) to Parkinson’sDisease Patients Who Exhibit End-Of-Dose Wearing-Off”Hoffmann-La Roche (1995)Investigator“A Parallel Group, Placebo-Controlled, Dose Ranging Study of Eldepryl 2.5 mg Tablets in Doses of 2.5,5, 7.5 and 10 mg QD versus Placebo in the Treatment of Patients with Parkinson’s Disease”Somerset Pharmaceuticals (1995)Investigator“A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Intramuscular BOTOX(Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Cervical Dystonia”Allergan Pharmaceuticals (1995-1997)Investigator“Tolerability of TVP-1012, a Novel MAO-B Inhibitor in Parkinsonian Patients”Lemmon/Teva (1996-1997)Investigator“Observer-blind, Randomized, Parallel-group Comparison of tolcapone and pergolide given incombination with Madopar (Levodopa/Benserazide) or Sinemet (levodopa/carbidopa) in Parkinsonianpatients who exhibit end-of-dose “wearing-off,” with open-label extension of tolcapone”Hoffmann La Roche (1996-1997)Investigator“Open-Label Study of Safety and Tolerability of Transdermal Selegiline in Mild to Moderate Parkinson’sDisease.”Somerset Pharmaceuticals Inc. (1996-1997)Investigator“A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study for the Safety,Tolerability and Efficacy of Daily, Oral Doses of Remacemide Hydrochloride in Patients with EarlyParkinson’s Disease.” (RAMP)Parkinson Study Group/Astra Merck, Inc. (1997-1998)Investigator

60“Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Clinical Trial for the Efficacy,Tolerability and Safety of Two Doses of Rasagiline in Early Parkinson’s Disease (PD) Patients NotTreated With Levodopa.” (TEMPO)Teva Pharmaceutical Industries, Ltd., Israel (1997-2000)Investigator“A Prospective, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Multi-Center Study toEvaluate the Short-Term Efficacy and Safety of Entacapone Administered Together with Levodopa inSubjects with Parkinson’s Disease without Motor Fluctuations.”Sandoz Pharmaceuticals Corporation (1997-2000)Investigator“Olanzapine vs. Placebo for Treatment-Associated Psychosis in Patients with Parkinson’s Disease.”Eli Lilly and Company (1997-1998)Co-Investigator“Phase III, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Two Dosesof Betaseron in Patients with Secondary-Progressive Multiple Sclerosis”Berlex Laboratories (1995-2000)Co-Investigator“A Long-term, Double-Blind Comparison of Tolcapone versus Placebo Given in Combination withLevodopa/AADC-I in Delaying the Onset of Motor Fluctuations in Parkinson’s Disease Patients Naive toLevodopa Therapy.” (DORF)Hoffmann La Roche (1997-1999)Investigator“Placebo-Controlled, Double-Blind Study of the Safety, Tolerability and Efficacy of the SelegilineTransdermal System (STS) in Parkinson’s Disease Patients Experiencing Sub-Optimal Responses toLevodopa/Carbidopa.”Somerset Pharmaceuticals (1997-2000)Investigator“Co-Enzyme Q10 and Remacemide: Evaluation in Huntington’s Disease (CARE-HD).”National Institutes of Health/Huntington Study Group (HSG) (1997-2002)Investigator“Sertraline for the Treatment of Depression in Parkinson’s Disease Patients.”(1997-2000)Investigator“An Open Label, Multicenter Clinical Evaluation of the Safety of Intramuscular BOTOX (BotulinumToxin Type A) Purified Neurotoxin Complex Manufactured from Neurotoxin Complex Batch BCB2024in the Management of Cervical Dystonia.”Allergan (1997)Investigator“A double blind, controlled, multicenter clinical trial of the safety and efficacy of transplanted fetalporcine cells in patients with Parkinson’s disease.”Diacrin/Genzyme (1998-2001)

61Investigator“A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study for the Safety,Tolerability and Efficacy of SIB-1508Y in Parkinson’s Disease Patients who are Requiring but notReceiving Dopaminergic Therapy.” (TEST-PD)SIBIA Neurosciences, Inc. (1997-1999)Investigator“A Multicenter, Double-Blind, Parallel-Group, Placebo Controlled Study of the effect on the progressionof Parkinson’s disease of Rilozole 50 mg BID or 100 mg BID for two years in 1050 patients.”Rhone-Poulenc Rorer (1998-2001)Investigator“A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study For The Safety,Tolerability And Efficacy Of Daily, Oral Doses Of Remacemide Hydrochloride In Levodopa TreatedParkinson’s Disease (PD) Subjects With Motor Fluctuations.” (REAL)Parkinson Study Group/Astra Merck, Inc. (1998-1999)Investigator“A Randomized, Double-Blind, Parallel-Group Study To Compare The Safety and Efficacy of ZYDISSelegiline 1.25 to 2.5mg Q.D. with Placebo as an adjunct in the Management of Parkinsonian Patientsbeing treated with Levodopa who exhibit deterioration in the quality of their response to this therapy.”Scherer DDS/Elan Pharmaceuticals (1998-2001)Investigator“Early vs. Late L-Dopa in Parkinson’s Disease (The ELLDOPA Study).”National Institutes of Health (1998-2001)Investigator“Usefulness of Tolcapone for the Treatment of Parkinson’s Disease Patients with Fluctuations andDyskinesia” (1998-2000)“Pramipexole-Ropinirole Switching Study in Advanced Parkinson’s Disease Patients on Levodopa”SmithKline Beecham (1998-2001)Investigator“A Double-blind, multicenter, flexible dose, l-dopa controlled study of ropinirole to investigateA) neuroprotective effect as measured by 3-D PET scanning , and B) opthalmological safety, in patientswith early Parkinson’s disease”SmithKline Beecham (1999-2001)InvestigatorEfficacy and Safety of Dysport® for the Treatment of Cervical Dystonia”Ipsen Limited (1998-2002)Investigator“A Multicenter, Randomized, Double-blind, Parallel Group Pilot Study Comparing TV-1203/CarbidopaDispersible Tablets with Standard Levodopa/Carbidopa Tablets in Advanced Parkinson’s Disease (PD)Patients with Response Fluctuations”Parkinson Study Group/TEVA Pharmaceuticals (1999-2002)

62Investigator“A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel group, MultiCenter, ExploratoryStudy of the Safety and Efficacy of KW-6002 as Adjunctive Therapy in Patients with Parkinson’sDisease Who Have Motor Response Complications on Levodopa/Carbidopa”Kyowa Pharmaceuticals (1999-2001)Investigator“A Multicenter, Open-label, Phase III Study for the Safety, Tolerability and Clinical Effect of RasagilineMesylate in Patients with Parkinson’s disease”TEVA Pharmaceuticals (1999-present)Investigator“A multi-national, multi-center, double-blind, placebo controlled study to evaluate the efficacy,tolerability and safety of glatiramer acetate for injection in Primary Progressive Multiple SclerosispatientsTeva Marion Partners (1999-2003)Co-Investigator“Parkinson’s Research: The Organized Genetics Initiative (PROGENI)”Parkinson Study Group/National Institutes of Health (1999-present)Investigator“Pilot Huntington At Risk Observational Study (PHAROS)”Huntington Study Group/National Institutes of Health (1999-present)Investigator“A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel group, MultiCenter, ExploratoryStudy of the Safety and Efficacy of KW-6002 as Adjunctive Therapy in Patients with Parkinson's DiseaseWho Have Motor Response Complications on Levodopa/Carbidopa”Kyowa Pharmaceuticals (1999 –2001)Investigator“A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Dose-Ranging Studyto Assess the Efficacy, Safety and Tolerability of Escalating Transdermal Doses of SPM 962 in Subjectswith Early Stage Parkinson’s Disease”Schwarz Pharma/Parkinson Study Group (1999 –2001)Investigator“Randomized, Double-blind, Placebo-controlled, Parellel-group, 6-month Safety, Efficacy, andNeuroimaging Trial of AMG-474-00 in the Treatment of Patients with Parkinson’s Disease”Amgen, Inc. (2000-2001)Investigator“An Open-label Extension Study of Remacemide Hydrochloride 300 mg bid in Subjects withHuntington’s Disease”(2000-2002)Investigator

63“Entacapone to Tolcapone Switch Study: To Determine Whether Tolcapone Can Improve PatientsReceiving Optomal Treatment with Entacapone”(2000-2002)Investigator“An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Subcutaneous Injectionsof Apomorphine in the Treatment of Off Episodes in Patients with On-Off or Wearing-Off EffectsAssociated with Late-Stage Parkinson’s Disease”Mylan Pharmaceuticals (2000 – 2003)Investigator“A Randomized, Controlled, Multicenter Clinical Study of the Efficacy and Safety of Fetal PorcineNeuronal Cells (NeuroCell-PD) Implanted Into Patients with Advanced Parkinson's Disease Compared toStandard Anti-Parkinson Medication Therapy Alone”Diacrin/Genzyme (2000 – present)Investigator“A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group Study Comparing TV-1203/Carbidopa Dispersible Tablets with Levodopa/Carbidopa Tablets in Advanced Parkinson’s Disease(PD) Patients with Motor Fluctuations”TEVA Pharmaceuticals (2000 – 2002)Investigator“A Multicenter, US and Canada, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study,for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson’s Diseasewith Motor Fluctuations.”TEVA Pharmaceuticals (2000-2002)Investigator“A Multicenter, Double-Blind, Placebo-Controlled Study of the Tolerability and Effect of Entacapone inParkinson’s Subjects with End-of-Dose Wearing Off Symptoms Occurring No Earlier than 4 Hours AfterTheir Most Recent Levodopa/Carbidopa Dose”Novartis (2001 – 2002)Investigator“An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc®; Botulinum ToxinType B) Injectable Solution in Patients with Cervical Dystonia”Elan Pharmaceuticals (2001-present)Investigator“Observational Study of BOTOX ® Use in Cervical Dystonia”Allergan (2001- 2005)Investigator“A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine themaximum well-tolerated starting dose of ropinirole controlled-release (CR) in Parkinson’s DiseasePatients not receiving other dopaminergic therapies “Skye-Pharma (2001-2002)Investigator

64“A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in the Treatment of EssentialTremor “Ortho-McNeil (2001-2004)Investigator“A non-interventional follow-up study to observe the long term outcome of Parkinson’s disease inpatients who completed Study SK&F 101468/056 or Study SK&F 101468125”SmithKline Beecham Pharmaceuticals (2001-2003)Investigator“A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability ofRasagiline Mesylate in Advanced Parkinson’s Disease (PD) Patients with Motor Fluctuations Treatedwith Chronic Levodopa/Carbidopa TherapyTEVA Neuroscience, LLC (2001-present)”Investigator“A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of Efficacy of TwoDoses of KW-6002 as Treatment for Parkinson’s Disease in Patients with Motor Response Complicationson Levodopa/Carbidopa TherapyKyowa Pharmaceuticals (2002- 2003)Investigator“A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy andSafety of CEP-1347 in Patients with Early Parkinson’s Disease (PRECEPT)”Cephalon, Inc./Parkinson Study Group (2002-present )Investigator“Double-Blind, randomized, placebo-controlled, multicenter study with two step group sequential designin patients with advanced idiopathic Parkinson’s disease to evaluate over twelve months the safety,tolerability and efficacy of 650,000 cultured retinal pigment epithelial cells attached to gelatinmicrocarriers (Spheramine®) implanted bilaterally (325,000 each side) into the postcommissuralputamen”Berlex Labs (2002-present)Investigator“A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tabletsto Patients with Parkinson’s Disease Who Completed the Previous Phase 2 Ropinirole CR Study-167”SkyePharma Inc. (2002-present)Investigator“A 12 Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safetyof Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS).”GlaxoSmithKline (2002)Investigator“A 52 Week Open-Label Extension Study of the Long-Term Safety of Ropinirole in Subjects Sufferingfrom Restless Legs Syndrome (RLS)”GlaxoSmithKline (2002-2004)Investigator

65“An Open-Label, Randomized, Two Part Study to Investigate the Relative Bioavailability of RopiniroleCR and IR Formulations and the Effects of Food on the Pharmakinetics of Ropinirole CR Formulations inEarly Stage Parkinson’s Disease Patients”SmithKline Beecham (2003-2004)Investigator“A Long-Term Multicenter, Open-Label, Safety Study with a Flexible Dose Range of KW-6002 asTreatment for Parkinson’s Disease in Patients with Motor Response Complications onLevodopa/Carbidopa Therapy”Kyowa Pharmaceuticals (2003-2004)Investigator“A 4-week, Multicenter, Open-label, Single Arm Study Assessing Tolerability of Triple Combination(TC) in Parkinson’s Disease Patients Who Experience End of Dose Wearing Off With Levodopa”Novartis (2003-2004)Investigator“A Multicenter, Double-Blind, Futility Study of Minocycline and Creatine in subjects with earlyuntreated Parkinson's Disease (PD).”NIH, National Institute of Neurological Disorders and Stroke (NINDS) (2003-present)Investigator“A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Efficacy andSafety of Sumanirole in Patients with Idiopathic Restless Legs Syndrome”Pharmacia (2003-2004)Investigator“A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in EarlyParkinson’s Disease Patients (Study for Proof Concept in Early Parkinson’s Disease of a Triple ReuptakeInhibitor, NS 2330/SCEPTRE)”Boehringer Ingelheim (2003-present)Investigator“A 12 Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safetyof Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS)”GlaxoSmithKline (2003-present)Investigator“A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of Six MonthsTreatment with Ropinirole CR as Adjunctive Therapy in Patients with Parkinson’s Disease who are notoptimally controlled on L-Dopa”GlaxoSmithKline (2003-present)InvestigatorAn Open-Label Extension Study with REQUIP (ropinirole) CR for subjects from studies 101468/165,101468/168 and 01468/169 (2004-present)Phase II, Multi-Center Placebo-Controlled, Double-Blind Trial, of ACP-103 in the Treatment ofPsychosis in Parkinson’s Disease.ACADIA Pharmaceuticals Inc. (2004-present)

66InvestigatorA Multicenter, Double-Blind, Pilot Study of CoQ10 and GPI 1485 in subjects with early untreatedParkinson’s Disease (PD),National Institute of Neurological Disorders and Stroke (NINDS) (2004-present)InvestigatorA two year Phase IIIb randomised, multicenter, double-blind, Sinemet-controlled, parallel group, flexibledose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa atincreasing the time to onset of dyskinesia in Parkinson’s disease subjects.GlaxoSmithKline (2003-present)InvestigatorA Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and GlobusPallidus for the Treatment of Parkinson’s DiseaseHines VA/NINDS (2004-present)InvestigatorEvaluation of the Efficacy and Safety of ALTROPANE for differentiating Parkinsonian Syndromes fromNon-Parkinsonian Syndromes in Patients with TremorsBoston Life Sciences, Inc. (2004-present)InvestigatorA 12 Week, Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter, Fixed DoseStudy to Evaluate the Efficacy and Safety of a 20 mg/d Oral Dose of KW-6002 (Istradefylline) AsTreatment for Parkinson’s Disease in Patients with Motor Response Complications onLevodopa/Carbidopa TherapyKyowa Pharmaceutical, Inc. (2004-present)Investigator

67Single Site Studies“Central and Peripheral Pharmacokinetics and Behavioral Effects of Levodopa Administered as StandardSinemet or Sinemet CR in Patients with Advanced Parkinson’s Disease”Dupont Merck Pharmaceuticals (1992-1996 )Investigator“Pharmacokinetics of Sinemet versus Sinemet Plus Deprenyl in Patients with Parkinson’s Disease”(1993-1996 )Investigator“Transplantation of Human Embryonic Striatal Tissue as a Treatment for Huntington’s Disease”(1996-)Investigator“A Pilot Study to Investigate the Causes of Fatigue in Parkinson’s Disease with Emphasis on the Role ofSleep Disorders, Followed by an Open-Label Trial of Modafinil in Patients Lacking a Defined Cause forFatigue” (2000 -)Investigator“Glutathione (GSH) In The Treatment of Parkinson’s Disease”Wellness Health Pharmaceuticals (2002-present)InvestigatorOther GrantsNINDS PD Neuroprotection Clinical Trial: Clinical Centers.Hauser RA, site PI. (Grant #1 U10 NS4-4425-01) $532,875. (2002-2007)“Parkinson’s Research: The Organized Genetics Initiative (PROGENI)” $85,455 (1999-2009)Grant from Wellness Pharmaceutical for Independently run trial:Glutathione (GSH) in the Treatment of Parkinson’s Disease $25,000 (2003-2008)Grant from the National Parkinson’s Foundation: NPF Care Centers of Florida $50,000/year (2001-2005)A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and GlobusPallidus for the Treatment of Parkinson’s Disease. $16,417,508 (2004-2010)

68UNIVERSITY AND COMMUNITY SERVICEDepartmental Representative, United Way Fund 1990Medical Student Applicant Interviewer 1990-1992Member, Professional Advisory Committee 1990-1995National Multiple Sclerosis Society,Florida Gulf Coast ChapterMember, LCME Committee 1990-1992On General Facilities and the LibraryUniversity of South Florida College of MedicineDepartment of NeurologyFaculty Council Representative 1992-1996University of South Florida College of MedicineDepartment of NeurologyResidency Committee 1994-1997University of South Florida College of MedicineDepartment of NeurologyResearch and Scholarly Productivity Committee 1994-1997University of South Florida College of MedicineDepartment of NeurologyResident Research Committee 1994-1997Tampa General HospitalNeuroscience MDCAdvisory Committee 1994-1995University of South FloridaPhysicians GroupPhysician Policies, Credentialing, andPeer Review Project Team 1995University of South FloridaHealth Sciences Research Committee 1995-1997University of South FloridaInstitute on AgingResearch Committee 1995-1997Tampa General Hospital 1998-2000Neuroscience CPIT

69Co-Chairman 1998 - 2000Dean’s Green and Gold Blue Ribbon Committee on ResearchUniversity of South Florida College of MedicineMember, Committee on Committees 1998-1999University of South Florida College of MedicineMember, Bylaws Committee 1998-1999University of South Florida College of MedicineMember, Executive Committee 1999-2002Department of NeurologyUniversity of South Florida College of MedicineMember, Neurosurgry Chair Search Committee 1999-2002University of South Florida College of MedicineMember, Ad Hoc Interdisciplinary Committee 2000-2001Tampa General HospitalMember, Curriculum Development Working Group 2000-2001University of South Florida College of MedicineMember, IRB Data Safety Monitoring Board 2000-2001University of South Florida College of MedicineMember, Managed Care CommitteeUniversity of South Florida College of MedicineMember, Billing and Integrity Compliance CommitteeUniversity of South Florida College of Medicine2001-present2002-presentUniversity of South Florida College of Medicine representative 2002-presentFaculty SenateUniversity of South FloridaMember, USF Faculty Senate committee on committees2002- present

70ADDITIONAL UNIVERSITY TEACHING ACTIVITIESDirector, Movement Disorder Fellowship 1994-2002Director, Fourth Year Medical Student Neurology Rotation 1998-2001Summer Research Fellowship in Neurology 1998Catherine WendellADDITIONAL NATIONAL TEACHING ACTIVITIESChairman, Newsletter Casexchange Series: Focus on 1998Parkinson’s DiseaseChairman, Newsletter Casexchange Series: Focus on 2000Parkinson’s DiseaseCONTINUING EDUCATIONAdvanced Trauma Life Support – 1983Advanced Cardiac Life Support – 1985Armed Forces Institute of PathologyNeuropathology Course - 1985Armed Forces Institute of PathologyNeuropathology Course - 1987Armed Forces Institute of PathologyNeuroradiology Course - 1987Electromyography UpdateMedical College of Virginia - 1987Update on InfectionEastern Virginia School of Medicine - 1987American Academy of Neurology Annual MeetingCincinnati, Ohio - 1988American Society of NeuroimagingNeuroimaging Course - Orlando, Florida 1989American Academy of Neurology Annual MeetingChicago, Illinois - 1989Risk Management Seminar

71University of South Florida, Tampa, Florida - 1989Update on AIDSUniversity of South Florida, Tampa, Florida - 1989Update on the Management of Seizure DisordersThe Epilepsy Foundation, Orlando, Florida - 1989American Society of NeuroimagingNeuroimaging Course - San Diego, California-1990First International Congress of Movement DisordersWashington, D.C.- April 23-28, 1990Parkinson’s Disease and Other Movement Disorders,Fourth Annual Symposium. Keystone, Colorado.February 27-March 1,1991 (12 hrs. CME)Medical Risk Management, Tampa, Florida,April 6, 1991. (5 hrs. CME)Epilepsy: Current Therapy and New Considerations. Hilton Head,South Carolina. May 24-26, 1991. (8.5 hours CME).HIV/AIDS Update. University of South Florida, Tampa, Florida.September 4, 1991. (1 Hr. CME).AIDS Update. Sheraton Grand Hotel. Tampa, Florida.September 10, 1991. (1 Hr. CME).Managing Movement Disorders in the 1990’s. San Diego,California. May 2, 1992. (3 Hrs. CME).American Academy of Neurology. 44 th Annual Meeting.San Diego, California. May 3-9, 1992. (63 Hrs. CME).The American Neurological Association. Toronto, Ontario,Canada. October 18-21, 1992. (17 CME Hours).American Society of Neuroimaging, 16 th Annual Meeting.Orlando, Florida, February 2-5, 1993. (15.5 CME Hours).Second Annual Headache Symposium. Tampa Marriott Westshore,Tampa, FL, April 23, 1994. (8 CME Hours).American Academy Of Neurology. 46 th Annual Meeting.Washington, D.C. April 29-May 8, 1994. (30 CME Hours).American Neurological Association. 119 th Annual Meeting.8 th Annual PSG/MODIS Symposia.

72San Francisco, California. October 8-12, 1994. (15 CME Hours)Third International Congress of Movement Disorders.Orlando, Florida. November 7-11, 1994. (25 CME Hours)Botulinum Toxin Seminar. Medical College of Georgia.Augusta, Georgia. September 21-22, 1994.Eighth Annual PSG Meeting. San Diego, California. February 23-February 25, 1995.American Society of Neural Transplantation. Second Annual Meeting. Clearwater,Florida. April 28-29, 1995.47 th Annual Meeting of the American Academy of Neurology. Seattle, Washington.May 7-May 13, 1995. (19.5 CME Hours)Domestic Violence Tampa General Healthcare. Tampa, Florida. September 21, 1995.(1.0 CME Hours)Worker’s Compensation Certified Training Course for Physicians. Tampa General HealthcareTampa, Florida. September 23, 1995. (5.0 CME Hours)48 th Annual Meeting of the American Academy of Neurology. San Francisco, California.March 23-30, 1996. (15.0 CME Hours)American Society of Neural Transplantation, third annual conference. Clearwater, Florida,April 25, 1996.Fourth International Congress of Movement Disorders. Vienna, Austria, June 17-21, 1996.49 th Annual Meeting of the American Academy of Neurology. Boston, MA. April 12-17, 1997.50 th Annual Meeting of the American Academy of Neurology. Minneapolis, Minnesota.March 26-February 1, 1998.MBA Program for Physicians. University of South Florida. May 24 – September 18, 1998.(50 CME Hours)MBA Program for Physicians. University of South Florida. October 1, 1998 – November 1, 1999.(50 CME Hours)1 st Annual Compliance Training for Faculty, Residents and Staff. University of South Florida.September 2, 1998.(1.0 CME Hours)Fifth International Congress of Movement Disorders. New York, NY. October 8-14, 1998.Neurology Grand Rounds. University of South Florida. January 1 – June 30, 1999.(4.0 CME Hours)

7351 st Annual Meeting of the American Academy of Neurology. Toronto, Ontario, Canada. April 18-22,1999.Sixth Annual Conference of the American Society for Neural Transplantation and Repair. Clearwater,Florida. April 30, 1999.HIV/AIDA Update. Domestic Violence Update. Tampa General Healthcare. September 8, 1999.(2.0 CME Hours)Research Compliance Conference. University of South Florida. October 9, 1999.(5.0 CME Hours)International Conference 1999: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins.Orlando, Florida. November 15-19, 1999.American Academy of Neurology 52 nd Annual Meeting. San Diego, California. April 29 – May 6, 2000.(9.5 CME Hours).American Academy of Neurology 53rd Annual Meeting. Philadelphia, Pennsylvania. May 6-12, 2001.American Academy of Neurology 54th Annual Meeting. Denver, Colorado. April 13-20, 2002.7 th International Congress of Parkinson’s Disease and Movement Disorders. Miami, FL. November 10-14,2002.ADVISORY BOARDS AND CONSULTANT MEETINGSTasmar Advisory Board meeting. Roche Laboratories. Vienna, VA. June 19,1997.Entacapone Cosultants meeting. Novartis. Buenos Aires, Argentina. September 14-15, 1997.Parkinson’s Disease/Ropinirole Neurology Advisory Board Meeting. SmithKline Beecham. Orlando, FL.November 21-23, 1997.Eldepryl Advisory Board Meeting. Watson Laboratories. New York, New York. March 13, 1998.Botox Advisory Meeting. Science and Technology Update. Scottsdale, Arizona. March 21-22.Novartis Advisory Board Meeting. Minneapolis, Minnesota. April 24-25, 1998.Roche Consultant’s Meeting. Minneapolis, Minnesota. April 30, 1998.Teva Consultant’s Meeting. New York, NY. July 17, 1998.SmithKline Advisory Board Meeting . Palm Springs, California. November 13-15, 1998.Roche Advisory Board Meeting. New York, NY. November 23, 1998.Athena Essential Tremor Advisory Board. San Francisco, California. March 3, 1999.

74Elan botulinum toxin Advisory Board. Napa Valley, California. July 30, 1999.Elan Essential Tremor Advisory Board. New York, New York. August 16, 1999.Novartis Comtan National Advisory Summit. Hamilton, Bermuda. September 14-16, 1999.AstraZeneca Huntington’s Disease Advisory Board. Arlington, Virginia. September 24-25, 1999.AstraZeneca Parkinson’s Disease Advisory Board. Toronto, Canada. October 15-16, 1999.NeuroCell-PD Advisory Meeting. Boston, Massachusetts. January 11, 2000.Botox Advisory Board (Allergan). Irvine, California. April 28, 2000.National Requip Advisory Board (SmithKline Beechum). San Diego, California. April 29, 2000.Elan Pharmaceuticals Neurology Advisory Board. San Diego, California. May 26, 2000.Solvay Pharmaceuticals SLV308 International Steeing Committee. Amsterdam, The Netherlands.September 29, 2000.Aventis Expert Advisory Panel (Riluzole). Rio Grande, Puerto Rico. December 1-3, 2000.Pharmacia US Advisory Board (Mirapex). Miami, Florida. January 10-12, 2001.Sarizotan International Advisory Board (Merck KgaA). New York, New York. March 8, 2001.Glaxo-SmithKline National Advisory Board (Requip). Charleston, South Carolina. March 23-24, 2001Pharmacia Global Thought Leadership Summit. Istanbul, Turkey. April 26-29, 2001.Glaxo-SmithKline National Advisory Board (Requip). Sonoma, California. October 12-14, 2001.Elan Regional Advisory Board Meeting (Myobloc). Atlanta, Georgia. November 17, 2001.Glaxo-SmithKline National Advisory Board (Requip). Keystone, Colorado. February 2, 2002.Allergan National Advisory Board (Botox). Atlanta, Georgia. April 5, 2002.Pharmacia National Advisory Board (Mirapex). Amelia Island, FL. June 21, 2002.Pharmacia. National Advisory Board (Mirapex). New York, NY. September 19, 2002.Glaxo-SmithKline. Clinical Consultants meeting (Requip CR). Philadelphia, PA. September 24, 2002.Teva Neuroscience Key Investigator meeting (Rasagiline). Chicago, IL. October 2, 2002.Novartis. End of dose wearing off (EODWO) working group meeting. New York, NY. October 3, 2002.Geron Consultancy Meeting. San Francisco, CA. November 15, 2002.

75Cephalon. Modafinil and PD Advisory Meeting. New Orleans, Louisiana. January 24, 2003.Glaxo-SmithKline. National Advisory Board. New Orleans, Louisiana. January 25, 2003.Novartis. TCH 346 Advisory Board Meeting. Short Hills, New Jersey. April 28, 2003.SPONSORED MEETINGS

76Tasmar Speaker’s Bureau Meeting. Tuscon, Arizona. March 6, 1998.Glaxo-SmithKline. Expert Forum Meeting. Dopamine Agonists and Neuroprotection in Parkinson’sDisease. Geneva, Switzerland. June 8-9,2001.Glaxo-SmithKline. Faculty development meeting. Chicago, Illinois, June 22-24,2001.Novartis. Extend the Reach Program. Presenter - Case Studies. Orlando, Florida. June 15-16, 2001.Novartis. Neurology Network Initiative: An educational Outreach Program. Presenter. Orlando, Florida.August 25, 2001.Novartis. Speaker Development Program. Miami, Florida. December 8, 2001.Novartis. Speaker Development Program. Las Vegas, Nevada. February 23, 2002.Pharmacia. International Neuroscience Conference. Budapest, Hungary. September 13, 2002.Allergan. SCIENCE – Summit Conference and Interdisciplinary Effort for Neurotoxin ComprehensiveEducation. San Juan, Peurto Rico. December 6-7, 2002.Novartis. End-of-dose wearing off (EODWO) working group meeting. Gstaad, Switzerland. February 19,2003.Novartis. End-of-dose wearing off (EODWO) working group meeting. London, UK. March 5, 2003.RECENT PROFESSIONAL MEETINGS12 th Annual Parkinson’s Disease Study Group. Las Vegas, Nevada. March 8-11, 1999.Sixth National Parkinson Foundation International Symposium. Miami, Florida. October 22-23.

77Neural Reconstruction Study Group, Inaugural Meeting. Miami, Florida. October 25, 1999.7 th Annual Huntington’s Disease Study Group. Palm Beach, Florida. November 4-6, 1999.13 th Annual Parkinson's Disease Study Group, Stuart, Florida. May 18-21, 2000.Huntington’s Disease Society of America Coalition for the Cure Research Conference. La Jolla,California. October 24-26.HSG 8 th Annual Meeting. La Jolla, California. October 28, 2000.First Annual Meeting of the Florida Movement Disorders Society. Jacksonville, Florida. November 3-2,2000.53 rd Annual Meeting of the American Academy of Neurology. Philadelphia, Pennsylvania. May 5-10,2001.14 th Annual Parkinson’s Disease Study Group meeting. Key Biscayne, FL. May 17-19, 2001.Huntington’s Disease Society of America 2 nd Annual Center of Excellence Conference. Atlanta, Georgia.September 15-16, 2001.AliProject Executive Council Meeting. Chicago, Illinois. October 1, 2001.Huntington Study Group 9 th Annual Meeting. Toronto, Canada. November 4-5, 2001.National Parkinson Symposium 7 th Annual Meeting. San Diego, California. November 8-9, 2001.54th Annual Meeting of the American Academy of Neurology. Denver, Colorado. April 14-20, 2002.15 th Annual Parkinson’s Disease Study Group meeting. Coronado, California. May 16-19, 2002.